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Bone is the second-most transplanted tissue after blood with more than 1.6 
million bone grafting procedures performed annually in the US at a cost of over 5 billion 
dollars. Treatment of large bone defects in particular remains one of the most challenging 
problems faced by orthopedic surgeons. Current therapies include bone grafts and/or 
delivery of osteoinductive proteins such as bone morphogenetic protein 2 (BMP-2). 
Despite advances in surgical technique and medical care, many of these treatment options 
still exhibit high variability in healing, suggesting that patient-specific factors, such as 
age, gender, immune status, and presence of certain co-morbidities may play a much 
more crucial role in treatment success than previously thought. Thus, the need to account 
for these patient-specific factors with more sophisticated treatment strategies has become 
increasingly apparent. 
The main objective of this work was to use preclinical animal models to 
investigate the influence of patient-specific factors on bone regeneration, with a particular 
focus on long-term immune profile characterization as it relates to the bone healing 
response after treatment. The impact of age and dose on large bone defect healing was 
assessed using a well-established bone injury rat model along with delivery of BMP-2 in 
a collagen sponge, which is the current clinical standard. We found that young rats healed 
better and were more responsive to increases in BMP-2 dose compared to adult rats, 
without experiencing greater complications. These results suggest that a more 
conservative dosing strategy may be the best approach for pediatric patients, for whom 
BMP-2 use is currently contraindicated and yet still occurs. Additionally, this work 
 xix 
sought to elucidate some of the key mechanisms that lead to impaired healing following 
nonunion, a significant clinical problem that still affects up to 10% of patients with long 
bone injuries. To accomplish this, a chronic nonunion model was established by delaying 
treatment to the bone defect by 8 weeks, after mineralized end-capping has occurred. We 
showed that delayed treatment after nonunion results in impaired healing compared to 
acute treatment of fresh defects. This new animal model can potentially serve as a more 
rigorous and clinically-relevant platform for studying nonunion and testing novel 
therapeutics. Finally, the issue of trauma-induced immune dysregulation following 
nonunion was investigated. We demonstrated differences in the local and systemic 
immune responses between acute and delayed treatment, and further showed that 
myeloid-derived suppressor cells (MDSCs) are a potential predictor of poor healing 
outcomes. Collectively, these studies have advanced our understanding of the factors that 
affect bone regeneration and represent a pivotal step towards improved, more 






CHAPTER 1. INTRODUCTION 
Large segmental bone defects, often the result of traumatic injury, wound 
debridement, tumor resection, or congenital deformity, remain one of the most 
challenging problems faced by orthopedic surgeons today. Current treatments involve 
bone grafts and/or delivery of osteoinductive proteins such as bone morphogenetic 
protein 2 (BMP-2). Unfortunately, the use of BMPs has been associated with increased 
inflammation, heterotopic bone formation, and osteolysis. Despite these risks, BMPs are 
still commonly used to treat large bone defects because there are currently no better bone 
graft substitutes. In many of these clinical cases there is high variability in patient 
outcomes, suggesting that patient-specific factors, including age, treatment timing, and 
immune status, may play a much more pivotal role in treatment success than previously 
thought. The main objective of this work is to use preclinical animal models to better 
understand how patient-specific factors influence bone regeneration, with a 
particular focus on exploring systemic immune profiling as a potential metric for 
monitoring the bone healing response after treatment. This will be accomplished in 
the following specific aims: 
1.1 Specific Aim I 
Investigate the effects of age and dose on gene expression and segmental bone defect 
repair following BMP-2 delivery 
The use of BMP-2 is currently contraindicated by the FDA for children due to 
concerns about side effects and the fact that very little is known about the appropriate 
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dosing for pediatric patients. Despite this warning and several documented cases of 
adverse reactions, off-label use of BMP-2 still occurs. By adapting our established 
segmental bone defect animal model to young and old rats, we will be able to identify 
age-related differences and hopefully provide guidance for developing better treatment 
strategies. Our hypothesis is that young animals will exhibit an increased inflammatory 
response to BMP-2 treatment but also have a lower BMP-2 dose requirement for healing 
compared to older animals. 
1.2 Specific Aim II 
Elucidate differences between healing and non-healing bone defects by assessing 
bone repair in a model of chronic nonunion 
Despite recent improvements to bone grafting procedures, complications such as 
delayed union and nonunion remain common, up to 10% in long bone injuries and 40% 
in spinal fusion cases. The pathophysiology of nonunion is poorly understood and the 
critical events that determine whether bones do or do not heal are not well known. 
Historically, the vast majority of bone regeneration research in animal models involve 
delivering treatment acutely, i.e. immediately after creation of the bone defect or other 
injury. For this aim, we seek to establish a model where the defects are first allowed to 
progress towards nonunion before any therapeutic intervention is performed. We believe 
this chronic nonunion model will be more challenging and better recapitulate the clinical 
scenarios of delayed union and nonunion, thus providing new insight into the 
mechanisms that lead to nonunion as well as improved treatment strategies. Our 
hypothesis is that chronic nonunion defects will demonstrate impaired healing compared 
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to acutely-treated defects due to differences in the inflammatory response after injury and 
treatment, including systemic inflammatory cytokine expression as well as the immune 
cell populations mobilized following injury. 
1.3 Specific Aim III 
Characterize the long-term immune profiles during acute and delayed treatment, 
and assess whether poor bone healing outcomes correlate with trauma-induced 
immune dysregulation 
Incidence of morbidity and mortality of severely injured trauma patients remains 
high, even with early treatment and surgical intervention. Recent evidence suggests that 
one major factor contributing to poor healing in these patients may be long-term immune 
dysregulation, specifically a persistent, low level inflammatory response that eventually 
leads to systemic chronic immunosuppression. Others have shown recently that this 
immunosuppressed state coincides with a rise in systemic myeloid derived suppressor 
cells (MDSCs) and a reduction in hematopoietic stem cell niches. We will characterize 
the long-term systemic immune profile of rats following segmental bone injury with 
acute or delayed treatment, as established in Aim II, using longitudinal blood analyses. 
As a complementary study, we will also investigate early local differences in 
inflammation between bone defects that received acute or delayed treatment. Our 
hypothesis for this aim is that delayed treatment will result in a dysregulated immune 
response compared to acute treatment, which can be quantified and correlated with long-
term bone healing outcomes. 
 4 
Overall, this work is significant as it addresses several important clinical issues and 
knowledge gaps with current bone treatment options. The impact of age on large bone 
defect healing will be elucidated using an established bone injury model along with 
delivery of rhBMP-2 in a collagen sponge, which is the current clinical standard. These 
results may provide valuable insight on a controversial subject: the use of rhBMP-2 in 
pediatric patients. Additionally, this work will seek to identify some of the key 
mechanisms that lead to nonunion, a significant clinical problem that affects up to 10% of 
patients with long bone injuries. A novel chronic nonunion model will be established that 
can potentially serve as a more rigorous and clinically relevant platform for testing new 
technologies and therapeutics. Finally, the issue of trauma-induced immune dysregulation 
will be explored in the context of bone healing, which will perhaps motivate future work 
on immunomodulatory treatment strategies to enhance bone repair. Collectively, these 
studies will advance our understanding of the complex factors that influence bone 
regeneration and represent a critical step towards improved, more personalized care and 
management of patients recovering from orthopedic trauma. 
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CHAPTER 2. BACKGROUND 
2.1  Clinical Significance of Bone Injuries 
 Bone is one of the unique tissues in the human body, along with liver and certain 
mucosal sites [1], that has capacity for scar-free repair. For humans, a bone defect is 
considered critical-size (i.e. one that will not spontaneously heal on its own) when it is 
approximately 2 cm in length [2]. Despite this fact, treatment of large bone defects often 
resulting from trauma, tumor resection, infection, or congenital deformity remains one of 
the most challenging problems faced by orthopedic surgeons. The current gold standard 
in treatment is autograft, most commonly harvested from the medullary cavity or iliac 
crest [3]. An estimated 1.6 million bone grafting procedures are performed annually in 
the US [4] and these procedures have an associated cost of over $5 billion [5]. However, 
these types of bone grafts have drawbacks such as limited tissue availability, donor site 
pain and morbidity, and additional healthcare costs associated with multiple surgeries. 
 Allografts from cadavers are used to a lesser extent but often have poor structural 
strength and demonstrate decreased osteogenesis compared to autografts [6], as well as 
carry additional risks of rejection and possible disease transmission. Bone graft 
substitutes, including demineralized bone matrix, hydroxyapatite composites, and bone 
morphogenetic proteins (BMPs), offer a promising alternative but are currently only 
approved for a select few indications [7]. BMPs in particular have been an area of intense 
research focus as these growth factors are among the most osteoinductive proteins 
discovered and have demonstrated some commercial success with Medtronic’s Infuse 
(rhBMP-2) and Stryker’s OP-1 (rhBMP-7) products. However, there have also been 
numerous reports of complications following BMP treatment [8-11] and as a result, 
BMPs have yet to be fully embraced by the orthopedic community. Thus, there seems to 
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be a great need to optimize BMP dosing and other currently available treatment options 
for each patient based their particular needs and circumstances in order maximize healing 
and minimize potential side effects. 
2.2 Influence of Aging on Bone Repair 
One of the most commonly cited factors that impacts bone healing is age. It has 
been well established that bone fractures in elderly patients do not heal as quickly and are 
more prone to complications compared to fractures in younger patients [12, 13]. A 
number of mechanisms have been implicated for this diminished bone healing capacity 
with age, including delayed angiogenesis [14], impaired stem cell recruitment and cell 
differentiation [15], poor callus mineralization [16], and increased presence of co-
morbidities like osteoporosis and diabetes mellitus [17, 18]. One group has even 
demonstrated that the bones of mice slowly lose their adaptive response to mechanical 
stimuli as they age [19]. Interestingly, others have shown that there are very few gene 
expression differences between young and old animals during fracture healing despite the 
latter group exhibiting a delayed healing response [20]. 
It is worth noting that all of the work referenced above and the majority of work 
found in literature on age-related differences in bone healing focus solely on fracture 
repair, and not the more challenging case of large bone defect repair, which may actually 
involve different endogenous mechanisms. Furthermore, none of the studies have directly 
investigated the role that age plays in the response to bone healing treatments, such as 
bone grafts or delivery of biologics. It remains to be seen whether patients of different 
ages require further considerations to determine the optimal treatment strategy. For 
example, even though autografts are usually assumed to be the gold standard, would it 
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actually be better for an older patient with a number of co-morbidities to receive an 
allograft (from a younger relatively healthy donor) supplemented with BMP instead? On 
the other end of the age spectrum, rhBMP-2 is currently contraindicated by the FDA for 
use in pediatric patients, but off-label use still occurs and no one has yet performed a 
controlled dosing study to determine if age significantly affects the response to rhBMP-2 
treatment. Such critical work is still needed to advance the field and improve therapeutic 
outcomes. 
2.3 Nonunion and Treatment Timing 
Although there has been significant progress in the treatment of bone injuries, the 
incidence of delayed union and nonunion remain high, up to 10% in long bone injuries 
and 40% in spinal fusion cases [21-23]. The clinical diagnosis of nonunion is often made 
when the injured bone demonstrates no radiographical evidence of union after 6 months 
and no visible signs of healing progression for 3 consecutive months [24, 25]. Nonunions 
can be further categorized as hypertrophic or atrophic depending on the level of callus 
formation. There are several known causes of nonunion including mechanical instability, 
inadequate vascularization, periosteal disruption, infection, and poor soft tissue coverage 
[26, 27]. Most hypertrophic nonunion cases are believed to be due to insufficient 
stabilization [27, 28], and are easily corrected with proper fixation. Atrophic cases are not 
as simple, and usually require more extensive fixation, resection of nonviable bone and 
fibrous tissue, and delivery of more grafts/biologics [29]. This process often occurs in a 
trial-and-error basis over the course of multiple revision surgeries, incurring long 
recovery times and increasing financial costs for the patient. This problem highlights the 
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fact that the underlying biological mechanisms of nonunion remain poorly understood 
and merit further investigation in appropriate preclinical models. 
A thorough review of literature revealed that most studies using preclinical animal 
models to research bone regeneration involve creation of some type of injury followed 
immediately by treatment. This is contrary to current clinical practice, as large bone 
defect injuries are often not given reparative treatment immediately (outside of wound 
stabilization) or even within the first couple weeks after injury. In fact, less than 7% of 
orthopedic surgeons surveyed support the idea of immediate bone grafting to treat 
segmental defects [3]. Instead, one of the increasingly used practices in treating large 
bone defects has been the Masquelet technique [30, 31]. This technique involves use of 
an antibiotic-doped polymethyl methacrylate (PMMA) cement spacer that remains in 
place for approximately 6-8 weeks, allowing most of the post-trauma inflammation to 
subside and a highly vascularized membrane to form around the defect. Subsequently 
during a revision surgery, the spacer is carefully removed with minimal disruption to the 
pre-formed membrane, and treatments such as autologous bone grafts are delivered. It has 
even been demonstrated that this vascularized membrane that forms around the defect 
secretes potent growth factors such as VEGF, TGFβ1, and BMP-2 and can also prevent 
resorption of the bone grafts [32, 33]. The recent establishment and increasing adoption 
of the Masquelet technique suggests a need to improve current preclinical models to be 
more representative of these clinical scenarios, possibly by incorporating delayed 
treatment. For critically-sized large bone defect models in particular, there remains a 
great opportunity to characterize some of the biological changes that occur with delayed 
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treatment and to provide further insight into some of the mechanisms that can lead to 
delayed union and nonunion. 
2.4 Inflammation and the Immune Response Following Trauma 
Immediately following any type of injury, inflammatory cytokines and danger 
signals called danger-associated molecular patterns (DAMPs) are released from the 
damaged tissue. Common DAMPs include intracellular molecules that normally are 
never found outside of the cell, such as many nuclear and cytosolic proteins, DNA, ATP, 
uric acid, and heat shock proteins [34, 35]. Presence of these DAMPs in the extracellular 
environment can be detected through binding of receptors, such as those in the Toll-like 
receptor (TLR) family [34, 36, 37]. Many TLRs and DAMPs are promiscuous and can 
actually bind to several different ligands and receptors, respectively, which can dictate 
the magnitude of the immune response generated as well as the specific pathways that are 
activated. For example, one of the most common DAMPs is the DNA chromatin-
associated high mobility group box 1 (HMGB1) protein, which can bind to both TLR2 
and TLR4 [38, 39]. Many groups have shown that using antibodies to target HMGB1 can 
knockdown specific TLR activation and even serve as an effective treatment strategy in 
animal models of sepsis [40, 41] and rheumatoid arthritis [42].  
Many of these TLRs are expressed on the cell or endosomal surface of innate 
immune cells, including mast cells, monocytes/macrophages, dendritic cells, and natural 
killer cells [43]. Binding of ligands to the respective TLR activates these immune cells 
and induces secretion of chemokines that recruit other immune cells to the wound area. 
Within minutes following trauma, the initial danger signals have been processed and 
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amplified, resulting in the classical inflammatory response: phagocytosis of cellular 
debris, neutralization and elimination of potentially harmful pathogens, increased 
systemic expression of inflammatory cytokines and local release of granular enzymes and 
reactive oxygen species (ROS), as well as recruitment of fibroblasts and endothelial cells 
to help stabilize the wound area and initiate revascularization. All of these local and 
systemic events constitute a normal acute inflammatory response to injury, and can also 
be referred to as the systemic inflammatory response syndrome (SIRS) [44].  
2.5 Chronic Immune Dysregulation and the Cellular Mediators 
The most difficult bone injury cases to treat are often the result of severe trauma, 
which involve substantial injury to bone and multiple soft tissues including vasculature, 
nerve, and muscle. The Centers for Disease Control estimates that trauma costs over $580 
billion annually and accounts for about 30% of all life years lost in the US [45].  While 
mortality rates following severe trauma have greatly decreased in recent decades, 
prolonged impairment and disability, both physical and mental, remain high even with 
acute medical and surgical care. Some have estimated that residual impairments prevail 
in up to 80% of severe trauma patients even three years after the initial trauma [46]. 
Recent studies have identified a dysregulated immune response, including chronic 
immunosuppression and immune paralysis, as an important cause of morbidity following 
severe trauma [47-49]. Trauma-induced immune dysfunction occurs roughly in two 
stages. The first stage encompasses the aforementioned SIRS phase, characterized by 
acute hyper-inflammation with overproduction of pro-inflammatory cytokines (IL-1, IL-
6, TNFα), countered by a compensatory anti-inflammatory response syndrome (CARS) 
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with increased expression of anti-inflammatory cytokines (IL-1Ra, IL-10, TGFβ) [50]. 
CARS follows almost immediately after SIRS is initiated, as prolonged exposure to the 
high levels of inflammatory factors and ROS generated during SIRS is damaging to the 
surrounding tissues and can lead to multiple organ dysfunction syndrome (MODS) if left 
unchecked [44, 51]. In most cases of uncomplicated healing, the SIRS and CARS 
responses eventually resolve one another and systemic immune homeostasis is restored 
within a couple weeks. Failure to achieve this balance can lead to a genomic storm of 
elevated pro- and anti-inflammatory signals that lasts up to 28 days post-injury [52], and 
will eventually result in a second stage called persistent inflammation, 
immunosuppression, and catabolism syndrome (PICS) [53]. PICS is often characterized 
by chronic low level inflammation combined with long term systemic immune 
suppression. Patients exhibiting symptoms of PICS are more prone to opportunistic 
infections, sepsis, MODS, and often require multiple surgical interventions and 
hospitalizations, which incur greater healthcare costs as well as increase the physical and 
emotional burden experienced by the patient  [53-55]. 
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Schematic depiction of the pro- and anti-inflammatory responses after trauma and 
how subsequent interventions/procedures can prolong immune disruption and 
increase the risk for MODS. Adapted from Brochner et al. [56]. 
 
Some of the primary cellular mediators of long-term immune paralysis observed in 
PICS are the immune suppressor cell types, including T regulatory cells (Tregs) and 
myeloid-derived suppressor cells (MDSCs) [48, 49, 54]. These cells suppress immune 
function by secreting anti-inflammatory factors such as IL-1RA, IL-10, and TGFβ, which 
can inhibit activation of other immune effector cell types, such as in T cell anergy, or 
even reduce immune populations over time by promoting premature apoptosis of these 
cells [54, 57-59]. Tregs are commonly identified as the CD4+FoxP3+CD25+ subset of T 
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helper cells, and are usually associated with a shift towards the anti-inflammatory Th2 
adaptive immune response [60, 61]. These immune suppressive cells have multiple roles 
in disease progression, and have been directly implicated in many autoimmune disorders 
[62] as well as in cancer tumor immune evasion [63, 64]. In the context of trauma and 
sepsis, it has been widely observed that Treg populations increase after injury and at the 
onset of septic shock [60, 65, 66], and they can induce rapid immune suppression through 
direct cell-to-cell contact with CD4+ and CD8+ T cells [67] as well as through Fas 
ligand-mediated apoptosis of  monocytes [68]. Not surprisingly, it has been shown that 
elevated circulating levels of Tregs and their cytokines were associated with higher 
incidence of sepsis and greater risk of mortality following severe burn injuries [69]. 
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Proposed conceptual model of PICS development after trauma/sepsis (Panel A) and 
the corresponding changes in immune cell populations (Panel B). This schematic 
describes a gradual rise of immunosuppressive cell types, particularly MDSCs, 
which coincides with a rapid decrease in macrophage and T cell numbers/function. 
Adapted from Gentile et al. [54]. 
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MDSCs are immature myeloid lineage cells originating in the bone marrow, 
separate from other myeloid immune cells such as macrophages, granulocytes, and 
dendritic cells [70]. While generally thought to be heterogeneous in nature, MDSCs are 
most commonly identified in rats as expressing both neutrophil (His48) and monocyte 
(CD11b) markers [71, 72]. These cells can directly suppress T cell function through 
depletion of the amino acid L-arginine [73], which is a critical mediator of T cell 
metabolism and activity [74], as well as through promotion of nitric-oxide-mediated T 
cell apoptosis [71]. Others have even shown that MDSCs are also involved in TGFβ1-
mediated suppression of natural killer cells [75] and can possibly enhance T regulatory 
cell survival [76]. In humans, circulating MDSCs have been observed to persist at high 
levels up to 28 days in severely septic patients, and were linked to adverse outcomes and 
prolonged ICU stays [59]. Similar to recent approaches that target Tregs, treatments that 
target MDSCs in order to mitigate immune suppression have been of great interest, 
particularly in the context of enhancing cancer immunotherapies [77]. 
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Age is a well-known influential factor in bone healing, with younger patients 
generally healing bone fractures more rapidly and suffering fewer complications 
compared to older patients. Yet, the impact age has on the response to current bone 
healing treatments, such as delivery of bone morphogenetic protein 2 (BMP-2), remains 
poorly characterized. It remains unclear how or if therapeutic dosing of BMP-2 should be 
modified to account for age-related differences, in order to minimize potential adverse 
effects and consequently improve patient bone healing outcomes. For this study, we 
sought to address this issue by using a preclinical critically-sized segmental bone defect 
model in rats to investigate age-related differences in bone repair following delivery of 
BMP-2 in a collagen sponge, the current clinical standard. Femoral defects were created 
in young (7-week-old) and adult (8-month-old) rats, and healing was assessed using gene 
expression analyses, longitudinal radiography, ex vivo micro-computed tomography 
(μCT), as well as torsional testing. We found that young rats demonstrated elevated 
expression of genes related to osteogenesis, chondrogenesis, and matrix remodeling at an 
early 1 week time point compared to adult rats. These early gene expression differences 
may have impacted long-term healing as the regenerated bones of young rats exhibited 
higher bone mineral densities compared to those of adult rats after 12 weeks. 
Furthermore, the young rats demonstrated significantly more bone formation and 
increased mechanical strength when BMP-2 dose was increased from 1 to 10 μg, a 
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finding not observed in adult rats. Overall, these results indicate there are age-related 
differences in BMP-2-mediated bone regeneration, including relative dose sensitivity, 
suggesting that age is an important consideration when implementing a BMP-2 treatment 
strategy. 
1
Portions of this chapter were adapted from A. Cheng*, L. Krishnan*, L. Tran, H.Y. Stevens, B. 
Xia, N. Lee, J.K. Williams, G. Gibson, R.E. Guldberg. The effects of age and dose on gene 




The repair of large bone defects represents one of the most challenging problems 
faced by orthopedic and craniofacial surgeons today. The gold standard in treatment is 
autograft [78], but graft substitutes and/or delivery of osteoinductive proteins such as the 
bone morphogenetic protein (BMP) family are also common alternatives with 
demonstrated efficacy in bone regeneration [79-81]. While the effects of age on 
endogenous bone healing have been well documented, both in preclinical animal models 
[15, 19, 20, 82-84] and human patients [12, 13, 17], the influence of age on the response 
to current bone healing treatments is much less informed. It has been demonstrated in 
vitro that age (as well as donor site) influences the responsiveness of bone marrow 
stromal cells to BMP-2 [85]. Indeed, clinical studies have shown similar trends, as use of 
BMP-2 and allograft in spine fusion in elderly patients (>65 years) demonstrated lower 
fusion rate and longer fusion time compared to younger patients (<65 years) receiving the 
same treatment [86]. Yamaji et al. also showed in vivo that the thickness of new bone 
formed when BMP-2 is injected into a palatal site is much lower in elderly 70-week-old 
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rats compared to young 10-week-old rats [87]. Importantly, this study also demonstrated 
an age-related difference in the osteoinductive response to increasing doses of BMP-2. 
While the elderly animals showed an increase in thickness of new bone over a large range 
of increasing BMP-2 doses (0 – 16 µg), the younger animals exhibited a much smaller 
benefit window (0 – 4 µg), beyond which a significant reduction in new bone thickness 
was actually observed. Additionally, the use of higher BMP-2 doses to enhance bone 
defect regeneration in mature rats (12-14 weeks of age) has been shown to result in 
heterotopic ossification and formation of abnormal spongy bone with thin trabecular 
networks [88, 89]. 
These results indicate that cells from younger animals are more responsive to 
BMP-2, which suggests that younger patients may respond better to lower BMP-2 doses, 
while older patients may not attain comparable responses even with higher BMP-2 
exposure [87]. However, the use of higher BMP-2 doses is fraught with risks including 
heterotopic mineralization, osteolysis, infection, and potentially life-threating 
inflammation/swelling, as extensively demonstrated in preclinical and clinical studies [8-
10]. These complications could potentially be most devastating in the pediatric 
population, with reports of massive inflammatory reactions and acute pain in some 
pediatric patients [90-92]. As a result, the use of any BMPs in skeletally immature 
patients is currently not approved by the U.S. Food and Drug Administration (FDA) [93]. 
Despite these known risks, off-label use of BMP-2 still occurs due to a lack of better 
alternatives in many scenarios, as well as documented successful cases without any 
noticeable complications [92, 94, 95]. In the absence of controlled trials to optimize 
therapeutic dosing (which remain unfeasible due to ethical considerations and costs), the 
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use of relevant preclinical animal models represent the best approach to gain insight into 
how age influences the response to BMP-2 treatment during bone healing. 
We have previously established a critically-sized segmental bone defect model in 
rats [96] to study bone regeneration and furthermore, have shown this model to be robust 
enough to qualitatively and quantitatively evaluate the efficacy of different treatments, 
including autograft and the clinical standard BMP-2 in collagen sponge [81, 97, 98]. 
Here, we adapted this model to 7-week-old young adolescent (young) and 8-month-old 
middle-aged adult (adult) rats in order to investigate how age impacts BMP-2-mediated 
bone repair at both a sub-healing low dose (1 μg) and relatively higher dose (10 μg) of 
BMP-2 [97]. We hypothesized that the osteogenic response would be a function of 
animal age, with young animals showing greater bone regeneration at the low dose and 
signs of supraphysiological levels of BMP-2 at the high dose, and the adult animals 
healing only at the high dose. We further hypothesized that young rats would demonstrate 
elevated early expression of genes related to bone healing as well as inflammation 
(particularly at the high BMP-2 dose), and this would correlate to improved long-term 
bone regeneration compared to the adult rats. Early (1 week post-surgery) gene 
expression profiles of young and adult animals at the two doses of BMP-2 were assessed 
by quantitative real-time polymerase chain reaction (qRT-PCR) to identify potential 
mechanistic differences. To compare bone regeneration, defect mineralization was 
monitored over time using longitudinal radiographs and end point micro-computed 
tomography (μCT) scans were analyzed for quantitative measures of new bone formation. 
Finally, the biomechanical properties of the regenerated femurs were measured by 
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torsional testing, serving as a functional metric to assess healing, while routine histology 
of harvested femora provided qualitative assessment of the newly formed bone. 
3.3 Materials and Methods 
3.3.1 Animals 
For these studies, 7-week-old and 8-month-old (retired breeders) male Sprague 
Dawley rats (Harlan Laboratories/Envigo) were used. Herein age refers to age at the time 
of surgery. Rats were pair housed in individually ventilated caging (Tecniplast) with a 
tunnel and gnawing blocks (Bio-Serv) for enrichment. Bedding was a mixture of corn cob 
and processed paper.   Purina Mills International #5001 was fed ad libitum. Filtered tap 
water treated with ultraviolet light was provided ad libitum in bottles. Sentinel results 
from Charles River Laboratories International Rat Prevalent PRIA testing were negative 
for all pathogens in the housing room. All animals were allowed to acclimate for at least 
2 weeks before any procedures were performed. Following each procedure, a divider was 
temporarily placed in the cage for better monitoring of post-operative recovery. Animals 
were randomly allocated to treatment groups. 
3.3.2 Surgical procedure 
All surgical procedures were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee. The surgical procedure has been described 
previously [96]. Anesthesia was induced and maintained using isoflurane (Henry Schein 
Animal Health) inhalation.  Briefly, an anterolateral skin incision was made in the thigh 
followed by blunt dissection to separate the overlaying muscles to reach the femur bone. 
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Limited extension of this muscle window allowed for placement of a radiolucent 
polysulfone fixation plate for internal stabilization. Critically-sized 8 mm defects were 
created in the mid-diaphysis of the femur using an oscillating saw. A collagen sponge 
loaded with BMP-2 was then delivered to the defect site, and finally the muscle and skin 
were closed using 4-0 vicryl suture and wound clips, respectively. Prior to surgery, all 
animals were given a subcutaneous injection of sustained-release buprenorphine 
(ZooPharm) for analgesia. 
3.3.3 Collagen sponge preparation 
The day before each surgery, BMP-2 (Pfizer) in 0.1% rat serum albumin (Sigma-
Aldrich) in 4 mM HCl solution was prepared and stored overnight at 4°C. Collagen 
sponge cylinders ~5mm in diameter and 10mm in length were created by biopsy punch 
from a sheet of collagen sponge (Kensey Nash/DSM). All collagen sponges were used 
directly from the manufacturer’s sterile packaging or sterilized by ethylene oxide if 
previously opened. During the surgery, the collagen sponge cylinders were transferred to 
a 24-well plate, and then 150 μl of the BMP-2 solution was carefully loaded onto each 
cylinder. The sponge was left for ~10 minutes to soak up any residual BMP-2 solution in 
the well before being gently press-fit into the bone defect. 
3.3.4 qRT-PCR and analyses 
At 1 week post-surgery, all tissue within the bone defect as well as a portion of the 
surrounding muscle were harvested and stored separately in RNAlater solution (Thermo 
Fisher Scientific) at 4°C. Bone and muscle tissue were similarly harvested from naïve 
age-matched animals for both age groups. Within 1 month of harvesting tissues, RNA 
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was isolated by following the QIAzol extraction method (Qiagen). RNA quality and 
concentration were assessed using the 2100 Bioanalyzer system (Agilent) and Nanodrop 
ND-1000 Spectrophotometer (Thermo Fisher Scientific), respectively. Subsequently, 300 
ng of RNA from each sample was converted to DNA using the RT2 First Strand cDNA 
kit (Qiagen) and then stored at -20°C (all remaining RNA was stored at -80°C). Samples 
and TaqMan primers (Thermo Fisher Scientific; see Table 2 for more detailed primer 
information) for 46 genes of interest were prepared for loading into 48.48 gene 
expression IFC chips (Fluidigm) according to the manufacturer’s protocols [99]. The 
chips were then primed, loaded with sample and primer reaction mixes, and then run 
through the BioMark System (Fluidigm). AccuRef rat universal cDNA (Gene Scientific) 
and distilled water were used as positive and negative controls, respectively, to ensure 
run fidelity. 
Table 1 - Summary of gene targets for qRT-PCR 
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Table 2 - TaqMan probe information for all primers 
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Auto-estimation of threshold cycle (Ct) was performed within the native Fluidigm 
software and the data exported for further processing. Variances of 5 housekeeping genes 
(Hprt1, Rplp1, Rpl13a, Gapdh, and Ppia) were examined and the three housekeeping 
genes with the lowest variance over all the runs were chosen for normalization (Gapdh 
and Ppia were excluded). Relative expression of genes of interest was determined by 
normalizing to the average of the three chosen housekeeping genes (Ct
Gene
 - Ct 
Arithmetic 
Mean of 3 HK
) for each sample [100]. Finally, the normalized expression values were 
inverted by subtracting from 31 (1 greater than the highest observed cycle number), 
which allowed for more straightforward analysis – higher adjusted Ct numbers represent 
higher relative expression levels. These data were then imported into JMP Genomics 8 
software (SAS Institute Inc.) and analyzed using the basic expression workflow module. 
Principal variance component analysis (PVCA) was performed to determine the 
proportion of variance for each of the major principal components explained by age, 
BMP-2 dose, and their interaction components, and the principal components were 
examined visually to assess the degree of sample clustering on scatter plots. Hierarchical 
clustering analysis allowed grouping of samples according to similarity in expression 
profiles. Subsequently, significant differences in gene expression for this data set of 75 
samples and 46 genes in our array were assessed using ANOVA and gene-specific linear 
modeling [101], controlling for multiple comparisons with a 5% Benjamini-Hochberg 
false discovery rate (FDR). The sample sizes for each group were: Young, unoperated (n 
= 7), Young, 1 μg BMP-2 (n = 8), Young, 10 μg BMP-2 (n = 7), Adult, unoperated (n = 
6), Adult, 1 μg BMP-2 (n = 5), Adult, 10 μg BMP-2 (n = 5). 
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3.3.5 Radiography and micro-computed tomography 
To qualitatively assess longitudinal bone regeneration, 2D in vivo digital 
radiographs were acquired with an MX-20 digital machine (Faxitron X-ray Corp) at 2, 4, 
8, and 12 weeks post-surgery. Bridging scores were assigned to each radiograph by two 
blinded investigators where bridging was defined as continuous bone spanning the entire 
defect space (from bone end to bone end). In instances of disagreement, a third blinded 
investigator served as tiebreaker. New bone formation was quantitatively evaluated using 
3D micro-computed tomography (μCT) at 12 weeks post-surgery. Ex vivo scans of the 
harvested femora were performed before mechanical testing using the vivaCT40 (Scanco 
Medical) at a 21 μm voxel size, 55 kVp voltage, and a 145 μA current. A threshold 
corresponding to 50% of native cortical bone density was applied to segment bone 
mineral and identify newly regenerated bone, as established previously [96]; these 
thresholds were determined to be ~315.7 and 406.6 mg hydroxyapatite/cm
3
 for the young 
and adult animals, respectively. The volume of interest (VOI) consisted of the central 
5.54 mm (264 slices) of the 8 mm defect. Mineralization was further defined as 
orthotopic (defect bone volume), within a 6 mm circular contour which corresponded to 
the diameter of intact bone, or heterotopic (ectopic bone volume), which formed outside 
of the 6 mm circular contour, as established previously [88, 102]. All μCT and 
biomechanical test data were normalized to native bone values (unoperated contralateral 
femur) to account for normal growth-related changes with age and animal-to-animal 
variability. The sample sizes for each group were: Young, 1 μg BMP-2 (n = 9), Young, 
10 μg BMP-2 (n = 12), Adult, 1 μg BMP-2 (n = 10), Adult, 10 μg BMP-2 (n = 6). 
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3.3.6 Biomechanical testing 
Torsional testing to failure was performed as previously described [96]. Femurs 
were excised at 12 weeks post-surgery, wrapped in PBS-soaked gauze, and stored at -
20°C until testing could be performed. On the day of testing, samples were thawed, the 
surrounding soft tissues were excised, and the femora were first µCT-scanned, as 
described above. Subsequently, the fixation plate was removed so that the native bone 
ends could be potted in Wood’s metal (Alfa Aesar). The potted femurs were tested to 
failure in torsion at a rotation rate of 3° per second using the EnduraTEC ELF3200 
axial/torsion testing system (Bose). Failure strength was determined by locating the peak 
torque within the first 60° of rotation. Torsional stiffness was calculated by finding the 
slope of the linear region before failure in the torque-rotation plot. The sample sizes for 
each group were: Young, 1 μg BMP-2 (n = 9), Young, 10 μg BMP-2 (n = 12), Adult, 1 
μg BMP-2 (n = 10), Adult, 10 μg BMP-2 (n = 6). 
3.3.7 Histological characterization 
Two representative samples from each treatment group were harvested post-
mechanical testing and fixed in 10% neutral buffered formalin at room temperature for 48 
hours. Samples were then switched to PBS and sent to HistoTox Labs (Boulder, CO) for 
decalcification, processing, and Hematoxylin and Eosin (H&E) and Safranin-O staining. 
Picrosirius red staining was performed in-house according to established protocols. 
3.3.8 Statistical analyses and power calculation 
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All data are reported as mean ± standard error of the mean. Unless otherwise noted, 
significance was determined using 1-way analysis of variance (ANOVA) with multiple 
comparisons made by Tukey’s post-hoc test. In cases of unequal variances (according to 
the Brown-Forsythe test), the nonparametric equivalent Kruskal-Wallis test with Dunn’s 
post-hoc test was used instead. Significance was determined by a p-value < 0.05. All 
statistical calculations were performed using GraphPad Prism 7 software. Sample sizes 
were determined by performing a power analysis in G*Power software based on bone 
volume and maximum torque results obtained from previous studies. These power 
calculations, along with historical data using this segmental bone defect rat model, 
suggest a sample size of 7-8 is sufficient to give statistical differences between groups. 
3.4 Results 
3.4.1 Early gene expression characterization in regenerating bone 
Local gene expression of the regenerating bone defect tissue at 1 week post-surgery 
was assessed across a panel of 46 genes (Table 1). Pairwise scatter plots of the first 3 
principal components (Figure 1) demonstrated clear separation of unoperated controls 
from operated/treated groups along the principal component 1 (PC1) axis. Interestingly 
within the treated groups, the majority of samples clustered according to age rather than 
BMP-2 dose, as can be observed in PC2. There was slight separation along PC3 
according to BMP-2 dose, but this split was not as obvious as in PC1 and 2.  
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Figure 1 - Principal component analysis of bone defect gene expression at 1 week. 
PCA scatter plots revealed sample segregation across multiple principal components. The 
PC1 axis exhibited distinct separation between unoperated controls (which are 
highlighted in the left panel) from treated samples. Furthermore, among the treated 
samples, there was separation based on age along PC2 (irrespective of BMP-2 dose), as 
can be seen in the middle panel with the adult (purple and green) and young (orange and 
yellow) samples highlighted. Finally, the panel on the right indicates slight separation 
based on dose along PC3 between the l μg (orange and purple) and 10 μg (yellow and 
green) BMP-2 samples. 
These observations were verified by hierarchical clustering analysis (Figure 2), which 
also showed overall clustering of treated samples based on age rather than BMP-2 dose. 
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Figure 2 - Hierarchical clustering of bone defect samples at 1 week. Heatmap 
revealed gene expression clustering primarily according to age, rather than BMP-2 dose, 
as well as clear separation of unoperated controls. Expression levels are represented on a 
scale of lower (blue) to higher (red) relative expression. Green squares denote significant 
difference (p<0.05) in expression of corresponding gene between young and adult 
animals at one or both BMP-2 doses (excluding unoperated controls). 
After removing the unoperated samples from the analyses, we used ANOVA to 
further evaluate the contributions of age and BMP-2 dosage to the expression of each 
gene. Overall, the young animals demonstrated elevated expression of genes related to 
osteogenesis (Figure 3A) compared to adult animals, including Runx2, Osx/Sp7, Col1a1, 
Opg, and On/Sparc and the osteoclastogenesis gene, Rankl. Similarly, the young rats also 
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had higher expression of chondrogenic genes Sox9, Col2a1, Acan, and Frzb, as well as 
matrix remodeling genes Mmp2 and Mmp13 (Figures 3B and 3C, respectively) compared 
to adults.  
 
Figure 3 - Expression differences for select genes in bone defect tissue at 1 week. 
Overall, young rats demonstrated elevated expression of genes relating to osteogenesis 
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(A), chondrogenesis (B), and matrix remodeling (C) at 1 week, particularly at the higher 
10 μg BMP-2 dose. There were relatively few inflammatory gene differences (D), as the 
young rats exhibited lower expression of Mcp1 but higher expression of Csf1. There was 
no significant effect of BMP-2 dose on gene expression for either age group. #p<0.05, 
##p<0.01, ###p<0.001, ####p<0.0001 vs. adult of same dose, n=5-8/group. 
There were relatively few inflammatory (Figure 3D) or myogenic (Figure 4) gene 
expression differences: expression of Csf1 and Myog were increased while Mcp1 
expression was decreased in young rats.  
 
Figure 4 - Myogenic and angiogenic gene expression in bone defect tissue at 1 week. 
Young rats showed elevated expression of Myog compared to adult rats at the 10 μg 
BMP-2 dose. #p<0.05 vs. adult of same dose, n=5-8/group. 
Surprisingly, differential gene expression with respect to BMP-2 dosing was much 
reduced relative to the effect of age. Many of these gene expression differences were 
validated with a linear model approach controlling for multiple comparisons using a 5% 
FDR criterion (Figure 5). This analysis revealed 21 significant gene expression 
differences between young and adult rats (Figure 5A), of which only 1 or 2 are expected 
to be false positives. Similar to what was observed with ANOVA, there were very few 
BMP-2 dose-related differences (Figure 5B). Only Osx exhibited decreased expression at 
the low 1 μg dose. Although very few significant differences were attributed to BMP-2 
dose, the PCA results (separation observed in PC3) suggest that a larger sample size may 
have increased power sufficiently to enable detection of more dose-dependent effects. 
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Figure 5 - Significant gene expression differences at 1 week using linear model 
approach with FDR. There were 21 differentially expressed genes between young and 
adult animals (A), many of these overlap with those identified by ANOVA in Figure 2. In 
contrast, there was only 1 differentially expressed gene between the two BMP-2 doses 
(B): Osx expression was significantly lower in the samples that received 1 μg BMP-2 
compared to 10 μg. All genes that are above the dashed red line are significant at a false 
discovery rate (FDR) of 0.05. 
 
3.4.2 Evaluation of new bone formation 
Radiographical assessment at 12 weeks (Figure 6A) demonstrated that both the 
young and adult rats had qualitatively lower bone mineral formation at the low 1 μg 
BMP-2 dose; less than 50 percent of defects bridged in both groups (3/9 for Young 1 μg, 
4/10 for Adult 1 μg). In contrast, at the higher 10 μg BMP-2 dose, both groups had more 
robust bone formation and all defects were bridged by 12 weeks (12/12 for Young 10 μg, 
7/7 for Adult 10 μg). Micro-computed tomography (μCT) reconstructions (Figure 6B) 
supported these observations and showed a clear BMP-2 dose effect on bone formation 
for both age groups.  
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Figure 6 - Representative radiographs and 3D microCT reconstructions of femoral 
bone defects. 4 and 12-week radiographs (A) and 12-week μCT reconstructions (B) 
demonstrated a clear effect of BMP-2 dose on new bone formation for both age groups. 
The low 1 μg BMP-2 dose resulted in poor bone regeneration with impaired defect 
bridging (<50% for both ages) while the higher 10 μg BMP-2 dose resulted in much more 
robust bone formation and 100% bridging for both age groups. In addition, the 
morphology of the newly formed bone at the 10 μg BMP-2 dose appeared more mature 
and organized from the μCT cross-sectional view, particularly in the young rats. 
Quantitative μCT analysis did not yield any differences in defect bone volume 
between age groups at either of the BMP-2 doses, but the young rats demonstrated a clear 
BMP-2 dosing effect in forming significantly more defect bone at the higher BMP-2 dose 
while the adult rats did not (Figure 7A). Furthermore, the newly formed bone in the 
young rats exhibited significantly higher bone mineral density at both doses compared to 
that of the adult rats (Figure 7B). 
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Figure 7 - Quantitative microCT and biomechanics analysis of regenerated bone at 
12 weeks. μCT analysis of defect bone volume (A) revealed young rats regenerated 
significantly more bone in the defect when BMP-2 dose was increased from 1 to 10 μg. 
In contrast, the adult rats exhibited no significant increase in defect bone formation with 
increasing BMP-2 dose. The regenerated bone in young rats also exhibited higher bone 
mineral densities (B) at both BMP-2 doses compared to adult rats. Finally, torsional 
testing of the regenerated femurs revealed a significant dose-dependent increase in 
maximum torque (C) and torsional stiffness (D) for the regenerated defects of young rats 
only. There were no significant differences in mechanical properties between the age 
groups at either dose level. *p<0.05, **p<0.01, ***p<0.001 as indicated. #p<0.05, 
##p<0.01, ###p<0.001 vs. adult of same dose, n=6-12/group. 
3.4.3 Biomechanical properties of regenerated bone 
Torsional testing of the harvested femurs revealed functional differences in the 
strengths of the regenerated bones. The maximum torque to failure (Figure 7C) and 
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torsional stiffness (Figure 7D) were significantly increased with BMP-2 dose only for the 
young animals, while the adult animals demonstrated no significant BMP-2 dosing effect. 
Within each dose level, these mechanical parameters were not significantly different 
between young and adult animals. Thus, as seen with the μCT results, the young animals 
demonstrated a significant improvement overall, with increased BMP-2 dosing resulting 
in better functional biomechanical properties. 
3.4.4 Histological characterization 
Representative samples from each treatment group were sectioned and stained with 
Hematoxylin and Eosin (H&E), Safranin-O and Fast Green (Saf-O), and Picrosirius red. 
H&E staining (Figure 8A-D) revealed clear morphologic differences in the tissues 
formed within the bone defect, particularly between the low and high BMP-2 dose 
samples. Areas of new bone formation were observed in all samples, but these areas were 
much larger and more widespread throughout the defect in the high dose BMP-2 samples 
of both age cohorts. Furthermore, the high dose BMP-2 samples exhibited formation of 
marrow-like structures directly adjacent to these areas of new bone formation. In contrast, 
the low dose BMP-2 samples demonstrated only small sparse islands of new bone 
formation surrounded by mostly fibrous tissue with cellular infiltrate (as indicated by the 
many nuclei). 
Saf-O staining (Figure 8E-H) revealed negligible cartilage present in the defect at 
12 weeks post-surgery for all groups. Finally, Picrosirius red staining (Figure 8I-L) and 
visualization under polarized light demonstrated that the 10 μg treated samples in each 
age group had more areas of collagen fiber alignment in the areas of new bone formation, 
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indicative of mature lamellar bone. Conversely, the 1 μg treated samples exhibited a 
much more disorganized collagen structure, typical of woven bone deposition. 
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Figure 8 - Histological staining of bone defects at 12 weeks. H&E staining (A-D) of 
representative sections from each group revealed interesting morphological differences. 
For both age groups, the 10 μg BMP-2 dose samples demonstrated many large islands of 
new bone formation (denoted by the asterisk symbol) and more prevalent marrow-like 
structures (denoted by the letter m) directly adjacent to these areas of new bone. This is in 
contrast to the 1 μg BMP-2 dose samples, which demonstrated much fewer and smaller 
areas of new bone formation that were primarily surrounded by soft, fibrous tissue. No 
positive Safranin-O staining (E-H) was observed within the defect space for any of the 
samples. Picrosirius red staining (I-L) of collagen fibers demonstrated that much of the 
new bone formed, particularly in the 10 μg BMP-2 samples of both ages, were more 




The use of BMP-2 clinically, both for on-label and off-label indications, remains a 
highly contentious topic due to its potential for detrimental side effects. In July 2008, six 
years after the initial approval of BMP-2 use in humans, the FDA issued a black box 
warning for BMP-2 in cervical spine applications due to potential life-threatening 
complications [103]. Furthermore, a recent study noted that many of the original 
industry-sponsored clinical trial publications concerning BMP-2 safety and efficacy had 
under-reported adverse events [104]. To date, BMP-2 is only approved for three 
indications: lumbar spine fusion, open tibial fractures, and sinus/alveolar ridge 
augmentations [105]. And yet, off-label use remains prevalent. This is despite two recent 
reports describing unapproved use in 66% and 79% of cases reporting adverse events to 
the FDA, respectively [106, 107]. The continued use of BMP-2 by clinicians in this 
manner suggests the lack of potential alternatives as well as the recognized benefits of 
BMP-2 therapy. However, it also highlights the insufficient guidelines currently in place 
on how to best implement BMP-2 therapies, and further underscores our poor 
fundamental understanding of the biological factors that influence BMP-2-mediated bone 
repair. 
One patient population who could benefit most from improved BMP-2 treatment 
strategies are pediatric (skeletally immature) patients, for whom all BMP use is currently 
contraindicated and yet still occurs [93]. Presently, very little is known about the 
influence of age on the efficacy of BMP-2 treatment and whether dosing should be 
adjusted to mitigate potential adverse events. In this work, we sought to address this 
important problem by studying BMP-2-mediated healing in a preclinical large segmental 
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bone defect model in rats. To the best of our knowledge, this work represents the first 
study to directly assess how young and adult rats respond to a clinically-approved bone 
healing therapy: BMP-2 delivered in a collagen sponge. 
Early gene expression analysis revealed that young rats have an elevated expression 
of many critical genes involved in the normal bone healing response. This partially 
contradicts findings from another group [20, 108], which showed that young, adult, and 
elderly rats all had similar overall levels of increased skeletal gene expression following 
femoral fracture, despite delayed union in the older cohorts. The main difference found in 
their study was in the temporal expression patterns: young rats had higher levels of 
mRNA expression that peaked and then returned to baseline levels after 4 weeks, whereas 
many genes in the older animals remained upregulated up to 6 weeks after fracture [108], 
including markers of osteoblastic and osteoclastic activity [20]. It is worth noting that 
these studies utilized a different bone injury rat model, as a simple closed femoral 
fracture with limited stabilization represents a major change in injury severity and 
mechanical healing environment compared to large segmental defect repair with BMP-2 
treatment, and consequently may involve different signaling pathways and cellular 
processes. 
Interestingly, in the present study, there were very few early differences in 
inflammatory gene expression. Only Mcp1 and Csf1 were differentially expressed 
between young and adult rats. Both factors are involved in macrophage recruitment and 
function, which suggests an altered macrophage response and supports recent work 
highlighting the importance of tissue resident macrophages in bone homeostasis and 
repair [109]. The relative lack of inflammatory gene expression differences is more 
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surprising considering the obvious differences observed in the physical condition of the 
animals. The young rats seemed to tolerate the surgery relatively well: a few 
demonstrated some swelling that resolved without intervention within the first 2 weeks 
post-injury but most seemed to recover with no complications. In contrast, the vast 
majority of adult rats exhibited many more signs of prolonged distress (porphyrin 
staining, poor grooming, hunched posture, and weight loss) and several had to be 
euthanized early and excluded from the study due to declining health. Perhaps the chosen 
1 week time point was not early enough to detect the changes in local gene expression 
common to the acute inflammatory phase of bone healing, which has been suggested to 
peak within the first 72 hours post-injury [110, 111]. It is also possible that inflammatory 
gene biomarkers alone, despite our panel including many influential cytokines such as 
tumor necrosis factor, interferon gamma, and a range of interleukins, were insufficient to 
discern differences in inflammation. Instead, analysis of local immune cell populations or 
systemic immune profile characterization of serum and/or circulating cells might have 
been more informative for the time point chosen. 
Despite our long-term results indicating higher BMP-2 dose sensitivity with young 
rats, these did not result in more complications compared to adult rats, contrary to what 
one might expect, bearing in mind all the concerns with BMP-2 use in pediatric patients. 
Beyond massive inflammation, another common adverse effect of high dose BMP-2 
treatment is ectopic mineralization. However, in this study, the levels of ectopic 
mineralization were comparable between young and adult rats (Figure 9), if not 
marginally less in the young rats: 6/12 young and 5/7 adult rats had appreciable amounts 
of ectopic mineralization (> 5mm
3
) at the high 10 μg BMP-2 dose. Overall, the degree of 
 41 
ectopic bone was much lower than that observed in a previous study, involving a higher 
dose of BMP-2 [88]. Taken together, the relatively low levels of inflammation and 
minimal amounts of ectopic mineralization in the young rats suggest that these potential 
complications can be mitigated in pediatric patients, particularly if a conservative 
approach is taken that utilizes lower doses of BMP-2. 
 
Figure 9 - Quantification of ectopic mineralization at 12 weeks. μCT analysis 
revealed an increase in the number of samples demonstrating appreciable amounts of 
ectopic bone formation (>5mm3) in both young and adult animals, although this increase 
was not statistically significant. There were no differences in amount of ectopic bone 
between young and adult animals at either of the BMP-2 doses tested. 
An intriguing observation from this study was that early gene expression 
differences (or lack thereof) was not predictive of long-term healing outcomes. Most of 
the early gene expression differences were age-dependent whereas the long-term 
functional differences in bone formation and mechanical properties were primarily dose-
dependent, particularly in the young animals. This disconnect between early and late 
differences is not completely unexpected as this study only characterized gene expression 






















































and dynamic early healing environment. Moreover, quantification of mRNA transcripts 
can be an imperfect analog for protein levels, and this technique does not account for 
subsequent modulation of translational or post-translational regulators, all of which could 
influence protein synthesis and activity. It is thus likely that changes to these complicated 
and interdependent mechanisms may have influenced the healing and inflammation 
response with age, and were not completely captured here. 
One potential limitation of this work is the absence of a negative control group 
such as an untreated bone defect or treatment with collagen sponge only (no BMP-2). 
However, the main focus of this study was to investigate how age and BMP-2 dose 
impact the response to BMP-2 treatment, not how BMP-2 impacts healing compared to 
no treatment. Our group has also previously shown that empty bone defects or those 
receiving carrier alone with no BMP-2 exhibit little to no bone formation and never 
achieve functional bridging [97, 98, 112]. Furthermore, others have demonstrated that 
delivery of collagen sponge loaded with saline to critical size defects results in minimal 
bone formation and very low expression of osteogenic and angiogenic genes compared to 
BMP-2 treatment [113]. Consequently, we excluded untreated or collagen sponge only 
control groups given that they would provide limited new insight and prioritized 
assessment of the interactive effects of age and dose on BMP-2 treatment response. 
More extensive studies are needed to better understand the less robust bone healing 
response exhibited by older animals. Other groups have demonstrated that aging reduces 
fracture callus vascularization [14], decreases callus volume and cartilage/bone content 
[114], impairs osteogenic differentiation of bone marrow cells [115], and diminishes 
periosteal stem cell populations [116]. Further investigations into these aging-related 
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deficits and how they are impacted by treatments such as BMP-2 may reveal alternative 
approaches for optimizing current therapeutics as well as uncover potential targets for 
new therapies. 
In summary, the work presented here represents the first investigation into the role 
of age on BMP-2-mediated segmental bone defect repair using the current clinical 
standard, BMP-2 delivered in collagen sponge. We found that young rats exhibited 
elevated early expression of genes involved in bone healing, and were able to form better 
quality bone long-term. Of clinical significance, our results revealed a clear effect of age 
on BMP-2 dose sensitivity as young rats appeared more responsive to increases in dosing 
than adult rats, without experiencing a higher complication rate. These results suggest 
that adjusting BMP-2 dose based on age may be an advantageous strategy to help 
minimize the potential risks associated with BMP therapy. 
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CHAPTER 4. DELAYED TREATMENT OF BONE DEFECT 
NONUNION RESULTS IN IMPAIRED HEALING 
4.1 Abstract 
Delayed union and nonunion are a significant concern for many orthopedic 
procedures, including long bone fractures and spinal fusions. Treatment of nonunion 
often entails multiple revision surgeries that further increase the financial, physical, and 
emotional burden on patients. Unfortunately, the optimal treatment strategy for 
nonunions remains unclear in many cases, and the risk of complications even after 
revision procedures remains high. This is in part due to the fact that many of the 
biological mechanisms that inhibit proper bone healing and lead to nonunion are still not 
fully understood. And yet, few preclinical models directly investigate how healing is 
impacted after establishment of nonunion, with most instead primarily focusing on 
treatment immediately after a fresh bone injury. Here, we utilized a critical size femoral 
defect model in rats where treatment was delayed 8 weeks post-injury, after capping of 
the bone ends has been observed previously in this model. In this study, acute and 
delayed treatments with bone morphogenetic protein-2 (BMP-2) were assessed. We 
found that delayed treatment results in decreased bone formation and reduced mechanical 
strength compared to acute treatment, even if BMP-2 dose is increased from 2 to 5 μg. 
Interestingly, serum cytokine analysis at 20 weeks revealed potential chronic immune 
dysregulation after delayed treatment, with the non-responders (samples that did not 
exhibit bridging of the defect) demonstrating higher overall expression of inflammatory 
cytokines, including TNFα and IL-1β, compared to responders. These findings suggest 
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that re-establishing long-term immune homeostasis may be critical for successful bone 
healing, particularly after nonunion. 
4.2 Introduction 
Although there has been significant progress in the treatment of bone injuries, the 
incidence of delayed union and nonunion remain high, up to 10% in long bone injuries 
and 40% in spinal fusion cases [21-23]. The clinical diagnosis of nonunion is often made 
when the injured bone demonstrates no radiographical evidence of union after 6 months 
and no visible signs of healing progression for 3 consecutive months [24, 25]. Nonunions 
can be further categorized as hypertrophic or atrophic depending on the level of callus 
formation. There are several known causes of nonunion including mechanical instability, 
inadequate vascularization, periosteal disruption, infection, and poor soft tissue coverage 
[26, 27]. Most hypertrophic nonunion cases are believed to be due to insufficient 
stabilization [27, 28], and are readily corrected with proper fixation. Atrophic cases are 
not as simple, and usually require more extensive fixation, resection of nonviable bone 
and fibrous tissue, and delivery of more grafts/biologics [29]. This process often occurs 
in a trial-and-error basis over the course of multiple revision surgeries, incurring long 
recovery times and increasing financial costs for the patient. This problem highlights the 
fact that the underlying biological mechanisms of nonunion remain poorly understood 
and merit further investigation in appropriate preclinical models. 
The vast majority of studies using preclinical animal models to investigate bone 
healing involve creation of some type of injury followed immediately by treatment. This 
is contrary to current clinical practice, as large bone defect injuries are often not given 
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reparative treatment immediately (outside of wound stabilization) or even within the first 
couple weeks after injury. In fact, less than 7% of orthopedic surgeons surveyed support 
the idea of immediate bone grafting to treat segmental defects [3]. Instead, one of the 
increasingly used practices in treating large bone defects has been the Masquelet 
technique [30, 31]. This technique involves use of an antibiotic-doped polymethyl 
methacrylate (PMMA) cement spacer that remains in place for approximately 6-8 weeks, 
allowing most of the post-trauma inflammation to subside and a highly vascularized 
membrane to form around the defect. Subsequently during a revision surgery, the spacer 
is carefully removed with minimal disruption to the pre-formed membrane, and 
treatments such as autologous bone grafts are delivered. It has even been demonstrated 
that this vascularized membrane that forms around the defect secretes potent growth 
factors such as VEGF, TGFβ1, and BMP-2 and can also prevent resorption of the bone 
grafts [32, 33]. The recent establishment and increasing adoption of the Masquelet 
technique suggests a need to improve current preclinical models to be more 
representative of these clinical scenarios, possibly by incorporating delayed treatment. 
For critically-sized large bone defect models in particular, there remains a great 
opportunity to characterize some of the biological changes that occur with delayed 
treatment and to provide further insight into some of the mechanisms that can lead to 
delayed union and nonunion. 
 In this study, we sought to establish a model of chronic nonunion using a 
critically-sized femoral bone defect in rats, wherein treatment was delayed until 8 weeks 
following the initial injury. This time point was chosen because we have historically seen 
mineralized capping of the bone ends by 8 weeks in this model for defects that don’t heal, 
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which is analogous to one of the hallmarks of long bone nonunion seen clinically. We 
hypothesized that delayed treatment would result in impaired bone healing compared to 
acute treatment. Moreover, we also hypothesized that poor healing in this chronic 
nonunion model could be attributed to a dysregulated long-term immune response. Bone 
regeneration was evaluated through longitudinal radiographs and quantitative micro-
computed tomography (μCT). The biomechanical strengths of the regenerated bones were 
assessed by torsional testing to failure. Bone histomorphometry was used to further 
elucidate differences in the newly formed bone between acute and delayed treatment. 
Finally, end point characterization of immune cells and inflammatory cytokines were 
performed on isolated spleens and sera, respectively, for the delayed treatment samples. 
4.3 Materials and Methods 
4.3.1 Animals 
For these studies, 13-week-old female SASCO Sprague Dawley rats (Charles River 
Laboratories, Inc.) were used. Rats were pair housed in individually ventilated caging 
(Tecniplast) with a tunnel and gnawing blocks (Bio-Serv) for enrichment. Bedding was a 
mixture of corn cob and processed paper. Purina Mills International #5001 was fed ad 
libitum. Filtered tap water treated with ultraviolet light was provided ad libitum in 
bottles. Sentinel results from Charles River Laboratories International Rat Prevalent 
PRIA testing were negative for all pathogens in the housing room. All animals were 
allowed to acclimate for at least 2 weeks before any procedures were performed. 
Following each procedure, a divider was temporarily placed in the cage for better 
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monitoring of post-operative recovery. Animals were randomly allocated to treatment 
groups. 
4.3.2 Alginate BMP-2 preparation 
RGD-functionalized alginate (FMC BioPolymer) was reconstituted in MEM alpha 
(Thermo Fisher Scientific) to create a 2% w/v solution, as described previously [98]. 
Recombinant human bone morphogenetic protein 2 (BMP-2, Pfizer Inc.) was 
reconstituted in a solution of 0.1% rat serum albumin (Sigma Aldrich) in 4 mM 
hydrochloric acid and mixed with the alginate solution to yield 2 or 5 μg BMP-2 per 150 
μl of final solution. This alginate/BMP-2 solution was gelled with the addition of calcium 
sulfate (Sigma Aldrich) at a 1:25 volume ratio. Hydrogels were prepared under sterile 
conditions inside a laminar flow hood and stored overnight at 4°C before use in surgery 
the next day. 
4.3.3 Surgical procedures 
All surgical procedures were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee. Anesthesia was induced and maintained 
using isoflurane (Henry Schein Animal Health) inhalation. Prior to each procedure, all 
animals were given a subcutaneous injection of sustained-release buprenorphine 
(ZooPharm) for analgesia. Briefly, an anterolateral skin incision was made in the thigh 
followed by blunt dissection to separate the overlaying muscles to reach the femur bone. 
Limited extension of this muscle window allowed for placement of a radiolucent 
polysulfone fixation plate for internal stabilization. Critically-sized 8 mm defects were 
created in the mid-diaphysis of the femur using an oscillating saw. For the acutely-treated 
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animals, a poly-caprolactone (PCL, Sigma Aldrich) nanofiber mesh was carefully placed 
around the newly exposed bone ends and alginate loaded with BMP-2 was delivered via 
syringe injection through the mesh perforations. Subsequently the muscle and skin were 
closed using 4-0 vicryl suture and wound clips, respectively. In contrast, for the animals 
receiving delayed treatment, the bone defects were initially left empty (no treatment) and 
the muscle and skin were closed. At 8 weeks, a second procedure was performed on these 
animals where the original incision was re-opened to expose the fixation plate and femur. 
An oscillating saw was used to remove any mineralized end capping of the defects and 
any soft tissue ingrowth within the defect space was cleared to allow for placement of the 
PCL nanofiber mesh. Finally, alginate/BMP-2 was delivered and the muscle and skin 
were closed as before. 
4.3.4 Radiography and micro-computed tomography 
To qualitatively assess longitudinal bone regeneration, 2D in vivo digital 
radiographs were acquired with an MX-20 digital machine (Faxitron X-ray Corp) at 2, 4, 
8, and 12 weeks post-treatment. Bridging scores were assigned to each radiograph by two 
blinded investigators where bridging was defined as continuous bone spanning the entire 
defect space (from bone end to bone end). In instances of disagreement, a third blinded 
investigator served as tiebreaker. Longitudinal bone formation was quantitatively 
evaluated using 3D micro-computed tomography (μCT) at 4, 8, and12 weeks post-
treatment. In vivo scans of the harvested femora were performed before mechanical 
testing using the vivaCT40 (Scanco Medical) at a 38 μm voxel size, 55 kVp voltage, and 
a 145 μA current. A threshold corresponding to 50% of native cortical bone density was 
applied to segment bone mineral and identify newly regenerated bone, as established 
 51 
previously [96]. The volume of interest (VOI) consisted of the central 5.89 mm (155 
slices) of the 8 mm defect. 
4.3.5 Biomechanical testing 
Torsional testing to failure was performed as previously described [96]. Femurs 
were excised at 12 weeks post-surgery, wrapped in PBS-soaked gauze, and stored at -
20°C until testing could be performed. On the day of testing, samples were thawed, the 
surrounding soft tissues were excised, and the femora were first µCT-scanned, as 
described above. Subsequently, the fixation plate was removed so that the native bone 
ends could be potted in Wood’s metal (Alfa Aesar). The potted femurs were tested to 
failure in torsion at a rotation rate of 3° per second using the EnduraTEC ELF3200 
axial/torsion testing system (Bose). Failure strength was determined by locating the peak 
torque within the first 60° of rotation. Torsional stiffness was calculated by finding the 
slope of the linear region before failure in the torque-rotation plot. 
4.3.6 Histological analyses 
A representative sample from each treatment group was harvested post-
mechanical testing and fixed in 10% neutral buffered formalin at room temperature for 48 
hours. Samples were then switched to PBS and sent to HistoTox Labs (Boulder, CO) for 
decalcification, processing, and Hematoxylin and Eosin (H&E) and Safranin-O staining. 
4.3.7 Serum and spleen collection 
Blood was collected by cardiac stick (~3ml per sample) at 20 weeks and into 
serum collection tubes (Thermo Fisher Scientific) and allowed to clot at room 
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temperature for 30 minutes before storage at 4°C overnight. The following day, all tubes 
were centrifuged at 1500g for 10 min and the yellow (straw) serum was collected and 
stored at -20°C. Spleens harvested at 20 weeks were minced and frozen in 
cryopreservation media (80% FBS, 20% DMSO) at -80°C overnight before being 
transferred to a liquid nitrogen dewar for storage. 
4.3.8 Multivariate analysis of serum cytokines 
Serum collected at 20 weeks were analyzed for cytokines via Luminex multiplex 
array (Millipore). Partial least squares discriminant analysis (PLSDA) was conducted in 
MATLAB (Mathworks) using the partial least squares algorithm by Cleiton Nunes 
(available on the Mathworks File Exchange). All multiplexed signaling data were z-
scored, and then used as the independent inputs to the algorithm. An orthogonal rotation 
in the LV1-LV2 plane was used to choose a new LV1 that best separated responders and 
non-responders. 
4.3.9 Characterization of immune cells by flow cytometry 
Cryopreserved spleens were thawed and digested in 2 ml Opti-MEM I reduced 
serum medium (Thermo Fisher Scientific) with 2 mg/ml collagenase B (Sigma Aldrich) 
for an hour at room temperature. The digested tissues were then passed through 40 μm 
cell strainers (Thermo Fisher Scientific) and centrifuged at 500g for 5 minutes. Red blood 
cells were removed by brief incubation in RBC lysis buffer (eBioscience) and the 
remaining cells were resuspended in RPMI-1640 media (Sigma Aldrich) for antibody 
staining. Cells were stained for CD3, CD4, CD8, FoxP3, His48, CD11b, His36, and B220 
using manufacturer’s recommended protocols, and all samples were then run through an 
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Accuri C6 flow cytometer (BD Biosciences). All data were exported for analysis in 
FlowJo software. 
4.3.10 Statistical analyses and power calculation 
All data are reported as mean ± standard error of the mean. Significance was 
determined by t-test or analysis of variance (ANOVA) as appropriate, with multiple 
comparisons made by Tukey’s post-hoc test. Significance was determined by a p-value < 
0.05. All statistical calculations were performed using GraphPad Prism 7 software. 
Sample sizes were determined by performing a power analysis in G*Power software 
based on bone volume and maximum torque results obtained from previous studies. 
These power calculations, along with historical data using this segmental bone defect rat 
model, suggest a sample size of 7-8 is sufficient to give statistical differences between 
groups. 
4.4 Results 
4.4.1 Qualitative and quantitative evaluation of new bone formation 
Radiographs at 12 weeks post-treatment demonstrated clear differences between 
acute and delayed treatment (Figure 10). All acute 2μg treated defects achieved 
radiographic bridging while only 50% of delayed 2μg and 75% of delayed 5μg treated 
defects did so.  
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Figure 10 - Radiographic evaluation of regenerated femurs at 12 weeks post-
treatment. Two representative radiographs from each treatment group demonstrate much 
more variability in bone formation with delayed treatment. This is reflected in the 
bridging scores for each group as 100%, 50%, and 75% of defects were bridged by 12 
weeks post-treatment for acute 2 μg, delayed 2 μg, and delayed 5 μg treatment groups, 
respectively. 
These qualitative observations were supported by μCT quantification of new bone 
formation. The acutely-treated defects had significantly more bone formation at weeks 4, 
8, and 12 compared to both delayed treatment groups (Figure 11A). There were no 
observed differences in bone mineral density between any treatment groups (Figure 11B). 
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Figure 11 - Quantitative microCT and biomechanical assessment of regenerated 
bone defects. Acute treatment with 2 μg BMP-2 yielded more bone formation at all time 
points compared to delayed treatment, at both 2 and 5 μg (A). There were no observed 
differences in bone mineral densities (B). Acutely-treated defects also demonstrated 
higher max torque (C) and torsional stiffness (D) compared to both delayed treatment 
groups at week 12 post-treatment. However, acute treatment resulted in decreased max 
torque and increased torsional stiffness compared to intact control femurs. ***p<0.001 as 
indicated, ###p<0.001 vs. all other treatment groups, n=10-12/ treatment groups, n=30 
for intact control group. 
 
4.4.2 Measurement of bone biomechanics 
Functional assessment of the newly regenerated bone by mechanical testing 
revealed similar findings to μCT. The femurs that received acute treatment demonstrated 
greater torque to failure (Figure 11C) and higher torsional stiffness (Figure 11D) 
compared to both delayed treatment groups. All treated groups had significantly lower 
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torque to failure compared to intact control femurs at 12 weeks post-treatment. However, 
the acutely-treated defects were significantly stiffer than intact controls at this time point.  
4.4.3 Histological characterization 
H&E staining (Figure 12, top row) revealed several interesting morphological 
differences. Acute treatment resulted in many larger areas of new bone formation 
throughout the defect space, while delayed treatment (at both 2 and 5μg BMP-2 doses) 
resulted in smaller pockets of new bone. Furthermore, H&E also suggested minimal 
presence of chondrocytes in acutely-treated defects at 12 weeks post-treatment, whereas 
chondrocytes were more apparent in the delayed treated samples, particularly the delayed 
2μg group. These areas of cartilage formation were confirmed by Saf-O staining (Figure 
12, bottom row). Interestingly, Saf-O staining also revealed qualitatively more alginate 
remaining in the defect with acute treatment, and these alginate fragments were primarily 
adjacent to the large areas of new bone formation. 
 57 
 
Figure 12 - Bone defect histomorphometry at 12 weeks post-treatment. 
Representative hematoxylin and eosin staining (top row) revealed more widespread and 
larger areas of new bone formation with acute treatment compared to either delayed 
treatment group. Safranin-O staining indicated greater presence of chondrocytes still 
remaining within the defect space for delayed treatment, particularly at the 2 μg BMP-2 
dose. 
 
4.4.4 Serum cytokine analyses 
At 12 weeks post-treatment, serum was collected for all samples that received 
delayed treatment and subsequently analyzed across a panel of inflammatory cytokines 
(Figure 13).  
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Figure 13 - Heatmap of serum cytokine expression for delayed treatment samples. 
Serum cytokine expression at 12 weeks post-treatment was quantified via multiplex 
array. For these analyses, delayed treatment groups were pooled and then separated into 
responders (R) and non-responders (N) according to whether the defects exhibited 
bridging by 12 weeks post-treatment. 
Partial least squares regression showed distinct separation along LV1 based on 
responder or non-responder status, i.e. whether or not the defect was successfully 
bridged, irrespective of BMP-2 dose (Figure 14A). Overall, non-responders were 
correlated with much higher expression of inflammatory cytokines (IL-1β, GM-CSF, 
IFNɣ, and TNFα) as well as anti-inflammatory cytokines (IL-2 and IL-10) (Figure 14B). 
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Figure 14 - Partial least squares regression (PLSR) analysis of serum cytokine 
expression. Regression analysis revealed separation using latent variable 1 (LV1), 
correlating cytokine profile at 12 weeks post-treatment with responder/non-responder 
status (A). LV1 composition indicated non-responders were positively correlated with 
higher expression of many inflammatory and anti-inflammatory cytokines, including IL-
1β, GM-CSF, and IL-10 (B). 
These computational model results were further supported by direct comparison of 
responders and non-responders using t-test. These statistical analyses revealed that non-
responders had significantly higher levels of TNFα and IL-1β in serum at 12 weeks post-




Figure 15 - Select serum cytokine differences between non-responders and 
responders. Non-responders demonstrated elevated expression of inflammatory 
cytokines TNFα and IL-1β in serum compared to responders at 12 weeks post-treatment. 




The pathophysiology of nonunion remains poorly understood. While some causes 
have been identified and are fairly easy to identify and correct such as improper 
mechanical fixation, most others including infection, poor vascularization, and presence 
of other co-morbidities are much harder to address and the optimal interventions for these 
cases are unclear [22, 117, 118]. From a basic science perspective, development of 
reproducible animal models to study impaired bone healing has been difficult, 
particularly if deliberate mechanical instability is not the main driving force of nonunion 
[119]. 
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 Here, we utilized a critically-sized femoral defect in rats to establish a model of 
chronic nonunion by delaying treatment with BMP-2 until after nonunion has been 
established. We found that delayed treatment results in impaired bone regeneration 
compared to acute treatment. Interestingly, this deficit in healing was not easily overcome 
with an increase in BMP-2 dose, as the acute 2 μg BMP-2 group still formed significantly 
more bone and had mechanically stronger regenerated femurs compared to the delayed 5 
μg BMP-2 group. These results suggest that the healing environment of a regenerating 
bone may be substantially altered during the progression and even after nonunion has 
been established. This has been partially investigated clinically, as recent work analyzing 
human fracture biopsies demonstrated changes in the local expression of BMP and BMP 
inhibitors, and the relative proportion of these factors was indicative of subsequent 
healing outcome [120]. These findings were supported by another group that also 
investigated fracture callus and nonunion tissues, and observed differences in BMP and 
BMP inhibitor expression in the chondrocytes present in the tissues [121]. In addition, 
elevated levels of certain matrix remodeling proteins, specifically MMP-7 and MMP-12, 
has also been implicated in fracture nonunion in humans and these proteins were shown 
to actively bind and degrade BMP-2 in vitro [122]. 
While not directly assessed in this study, it is likely that the reparative capacity of 
local stem and osteoprogenitor cells are greatly diminished after nonunion. Indeed, recent 
work by Bajada et al. demonstrated that stromal cells isolated from human fracture 
nonunions exhibited reduced osteogenic and mineral-forming capacity as well as 
increased senescence compared to control bone marrow mesenchymal stromal cells 
[123]. Multiple other groups have also shown that proliferation of stem cells as well as 
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osteoblasts is impaired during nonunion [124, 125]. Taken together, it appears that 
osteogenesis is impaired during nonunion due to a reduction in the progenitor cells 
available at the site of injury and diminished ability of these cells that are present to 
differentiate into osteoblasts and produce new mineral. 
The Safranin-O staining showed greater presence of chondrocytes within the 
defect space for the delayed treatment group at 12 weeks post-treatment compared to the 
same time point for acutely-treated animals. This indicates perhaps an alteration in the 
normal endochondral ossification healing process, whereby treatment after nonunion 
induces a delayed or prolonged period of cartilage deposition that subsequently further 
delays the onset of mineralization. This could be verified in future studies by histological 
characterization at multiple time points during healing. 
Serum proteomics analysis using partial least squares regression at week 20 for 
the delayed treatment samples revealed non-responders were correlated with increased 
expression of many inflammatory factors. These long-term results are suggestive of a 
chronically dysregulated immune response in the animals that exhibited the worst healing 
responses. Others have described similar findings clinically in response to trauma [48, 50, 
54]. Vanzant et al. observed an increase in inflammatory gene expression with patients 
that experienced a complicated recovery (>14 days) compared to those that had a 
relatively uncomplicated recovery (<5 days) from multiple organ injury [55]. 
A limitation of the immune characterization work performed in this study was that 
only a single terminal time point (20 weeks) was analyzed. At this late time point, we 
found no significant differences in the spleen immune cell populations (Figure 16). It is 
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possible the bone injury alone in this model is not traumatic enough to cause severe 
immune dysfunction that persists for 20 weeks (12 weeks post-treatment). In fact, recent 
work in a burn injury model demonstrated that splenic inflammatory monocyte 
populations were only increased through 8 days postburn [126]. Only in a severe model 
of sepsis has widespread splenic alterations been observed beyond 14 days [127]. Apart 
from spleen characterization, immune cell profiling of a more proximal target to the 
femur, such as the inguinal lymph nodes, bone marrow, and even the surrounding 
quadriceps muscle may have been more informative. 
 
Figure 16 - Flow cytometry analysis of spleen for immune cells. No differences were 
observed in any spleen immune cell populations between non-responders and responders 
at 12 weeks post-treatment. n=8-12/group 
More work is needed to validate long-term immune dysregulation in this model of 
chronic nonunion. Longitudinal immune characterization at multiple time points post-
treatment would help elucidate the progression of immune dysfunction and perhaps 
reveal time points for early intervention. Moreover, these results could potentially 
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motivate new approaches for the clinical treatment of nonunion, such as additional 
treatment with some type of immunomodulatory therapy prior or in conjunction with a 
bone-healing therapy to improve patient outcomes. 
 In conclusion, the study presented here established a chronic nonunion model 
involving delayed treatment to critical size femoral defects in rats. Our results 
qualitatively and quantitatively demonstrated impaired healing compared to acute 
treatment, and this impairment could not be overcome with a modest increase in BMP-2 
dose. Interestingly, we found evidence of possible long-term immune dysregulation in the 
rats that received delayed treatment, as the worst responders in that cohort were 
associated with higher circulating levels of inflammatory cytokines, including TNFα and 
IL-1β. These results suggest that the long-term systemic immune response may be 
indicative of bone healing outcome, which consequently motivates more in-depth 




CHAPTER 5. IMMUNE DYSREGULATION FOLLOWING 
TREATMENT OF ESTABLISHED NONUNION 
5.1 Abstract 
Severe traumatic injuries involving extremities are quite prevalent in both military 
and civilian patients. These types of injuries are often associated with poor outcomes, 
including greater risk of complications, requiring multiple surgical procedures and longer 
hospital stays, and can result in long-term functional deficits that severely impact patient 
quality of life. Recent work has implicated immune dysregulation as an important risk 
factor following trauma. Failure to fully resolve inflammation following injury can 
eventually lead to chronic immune suppression that makes the patient much more 
vulnerable to opportunistic pathogens and even multiple organ dysfunction. Some of the 
main drivers of systemic immune suppression are immune suppressor cells, such as T 
regulatory cells and myeloid-derived suppressor cells (MDSCs). However to-date, very 
little is known about whether long-term immune suppression develops following bone 
injury, particularly in cases of poor healing such as nonunion, and how immune 
suppressor cells impact bone formation. 
The objective of this study was to elucidate whether long-term immune dysfunction 
develops during the progression and treatment of nonunion. Using a previously 
established femoral bone defect model of non-union in rats, we characterized the 
systemic and local immune profiles of animals through 20 weeks following acute or 
delayed treatment with BMP-2. We found that delayed treatment results in an altered 
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early local inflammatory response at 2 weeks post-treatment, and is correlated with lower 
expression of inflammatory mediators such as IL-4, MIP-1α, and IL-18 in the early 
defect. Furthermore, longitudinal systemic analyses of blood revealed that bone 
formation is strongly correlated with cytokines IL-6, LIX, and IL-13 and negatively 
correlated with IP-10. Interestingly, bone formation was also significantly negatively 
correlated with circulating MDSCs, as early as 1 and 2 weeks post-treatment. MDSC 
levels were also elevated in bone marrow at 20 weeks for delayed treatment compared to 
acute treatment. These results suggest that long-term immune dysregulation does play a 
role in nonunion, and that increased presence of MDSCs both systemically and locally 
may be predictive of poor bone healing outcomes. 
5.2 Introduction 
Musculoskeletal trauma involving extremities is quite common, occurring in up to 
71% of battlefield [128] and 59% of civilian injuries [129]. Recent studies have identified 
a dysregulated immune response, including chronic immunosuppression and immune 
paralysis, as an important cause of morbidity following severe trauma [47-49]. It has 
been hypothesized that trauma-induced immune dysfunction occurs roughly in two 
stages. The first stage encompasses a systemic inflammatory response syndrome (SIRS), 
characterized by acute hyper-inflammation with overproduction of pro-inflammatory 
cytokines (IL-1, IL-6, TNFα), countered by a compensatory anti-inflammatory response 
syndrome (CARS) with increased expression of anti-inflammatory cytokines (IL-1Ra, IL-
10, TGFβ) [50]. CARS follows almost immediately after SIRS is initiated, as prolonged 
exposure to the high levels of inflammatory factors and reactive oxygen species (ROS) 
generated during SIRS is damaging to the surrounding tissues and can lead to multiple 
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organ dysfunction syndrome (MODS) if left unchecked [44, 51]. In most cases of 
uncomplicated healing, the SIRS and CARS responses eventually resolve one another 
and systemic immune homeostasis is restored within a couple weeks. Failure to achieve 
this balance can lead to a genomic storm of elevated pro- and anti-inflammatory signals 
that lasts up to 28 days post-injury [52], and will eventually result in a second stage 
called persistent inflammation, immunosuppression, and catabolism syndrome (PICS) 
[53]. PICS is often characterized by chronic low level inflammation combined with long 
term systemic immune suppression. Patients exhibiting symptoms of PICS are more 
prone to opportunistic infections, sepsis, MODS, and often require multiple surgical 
interventions and hospitalizations, which incur greater long-term healthcare costs for the 
patient  [53-55]. 
Some of the primary cellular mediators of long-term immune paralysis observed in 
PICS are the immune suppressor cell types, including T regulatory cells (Tregs) and 
myeloid-derived suppressor cells (MDSCs) [48, 49, 54]. These cells suppress immune 
function by secreting anti-inflammatory factors such as IL-1RA, IL-10, and TGFβ, which 
can inhibit activation of other immune effector cell types, such as in T cell anergy, or 
even reduce immune populations over time by promoting premature apoptosis of these 
cells [54, 57-59]. MDSCs are immature myeloid lineage cells that originate in the bone 
marrow, separate from other myeloid immune cells such as macrophages, granulocytes, 
and dendritic cells [70]. While generally thought to be heterogeneous in nature, MDSCs 
are most commonly identified in rats as expressing both neutrophil (His48) and monocyte 
(CD11b) markers [71, 72]. These cells can directly suppress T cell function through 
depletion of the amino acid L-arginine [73], which is a critical mediator of T cell 
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metabolism and activity [74], as well as through promotion of nitric-oxide-mediated T 
cell apoptosis [71]. Others have shown that MDSCs are also involved in TGFβ1-
mediated suppression of natural killer cells [75] and can possibly enhance T regulatory 
cell survival [76]. In humans, circulating MDSCs have been observed to persist at high 
levels up to 28 days in severely septic patients, and were linked to adverse outcomes and 
prolonged ICU stays [59]. However, the influence of MDSCs following bone injuries, 
particularly in cases of poor healing such as nonunion, remains unclear. 
Herein, we utilized a previously established femoral bone defect model of chronic 
nonunion in rats to investigate potential immune dysregulation. In this model, treatment 
with BMP-2 is delivered 8 weeks after initial creation of the bone defect (delayed 
treatment), which is the time needed historically to see obvious radiographic evidence of 
nonunion establishment (mineralized capping of bone ends). Acute treatment (i.e. 
treatment delivered immediately following defect creation) was also investigated and 
represented an example of a relatively uncomplicated bone healing scenario. We 
hypothesized that delayed treatment would result in poor bone healing compared to acute 
treatment and furthermore, this impairment could be linked to chronic immune 
dysregulation involving MDSCs. First, the early healing environment was assessed 
through cytokine analysis of local bone defect tissue at 10 weeks, 2 weeks post-treatment. 
Next, a longitudinal study involving blood collection at weeks 0, 1, 2, 4, 8, 10, 12, 16, 
and 20 was performed to assess the systemic immune response over time. Blood collected 
at each time point was analyzed for multiple immune cell populations by flow cytometry 
as well for serum cytokines through multiplex array. These results were evaluated with 
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respect to bone healing, which was quantified by micro-computed tomography (μCT) at 
weeks 14 and 20 and biomechanical testing at week 20. 
5.3 Materials and Methods 
5.3.1 Animals 
For these studies, 13-week-old female SASCO Sprague Dawley rats (Charles River 
Laboratories, Inc.) were used. Rats were pair housed in individually ventilated caging 
(Tecniplast) with a tunnel and gnawing blocks (Bio-Serv) for enrichment. Bedding was a 
mixture of corn cob and processed paper. Purina Mills International #5001 was fed ad 
libitum. Filtered tap water treated with ultraviolet light was provided ad libitum in 
bottles. Sentinel results from Charles River Laboratories International Rat Prevalent 
PRIA testing were negative for all pathogens in the housing room. All animals were 
allowed to acclimate for at least 2 weeks before any procedures were performed. 
Following each procedure, a divider was temporarily placed in the cage for better 
monitoring of post-operative recovery. Animals were randomly allocated to treatment 
groups. 
5.3.2 Alginate BMP-2 preparation 
RGD-functionalized alginate (FMC BioPolymer) was reconstituted in MEM alpha 
(Thermo Fisher Scientific) to create a 2% w/v solution, as described previously [98]. 
Recombinant human bone morphogenetic protein 2 (BMP-2, Pfizer Inc.) was 
reconstituted in a solution of 0.1% rat serum albumin (Sigma Aldrich) in 4 mM 
hydrochloric acid and mixed with the alginate solution to yield 2 μg BMP-2 per 150 μl of 
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final solution. This alginate/BMP-2 solution was gelled with the addition of calcium 
sulfate (Sigma Aldrich) at a 1:25 volume ratio. Hydrogels were prepared under sterile 
conditions inside a laminar flow hood and stored overnight at 4°C before use in surgery 
the next day. 
5.3.3 Surgical procedures 
All surgical procedures were approved by the Georgia Institute of Technology 
Institutional Animal Care and Use Committee. Anesthesia was induced and maintained 
using isoflurane (Henry Schein Animal Health) inhalation. Prior to each procedure, all 
animals were given a subcutaneous injection of sustained-release buprenorphine 
(ZooPharm) for analgesia. Briefly, an anterolateral skin incision was made in the thigh 
followed by blunt dissection to separate the overlaying muscles to reach the femur bone. 
Limited extension of this muscle window allowed for placement of a radiolucent 
polysulfone fixation plate for internal stabilization. Critically-sized 8 mm defects were 
created in the mid-diaphysis of the femur using an oscillating saw. For the acutely-treated 
animals, a poly-caprolactone (PCL, Sigma Aldrich) nanofiber mesh was carefully placed 
around the newly exposed bone ends and alginate loaded with BMP-2 was delivered via 
syringe injection through the mesh perforations. Subsequently the muscle and skin were 
closed using 4-0 vicryl suture and wound clips, respectively. In contrast, for the animals 
receiving delayed treatment, the bone defects were initially left empty (no treatment) and 
the muscle and skin were closed. At 8 weeks, a second procedure was performed on these 
animals where the original incision was re-opened to expose the fixation plate and femur. 
An oscillating saw was used to remove any mineralized end capping of the defects and 
any soft tissue ingrowth within the defect space was cleared to allow for placement of the 
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PCL nanofiber mesh. Finally, alginate/BMP-2 was delivered and the muscle and skin 
were closed as before. 
5.3.4 Radiography and micro-computed tomography 
To qualitatively assess longitudinal bone regeneration, 2D in vivo digital 
radiographs were acquired with an MX-20 digital machine (Faxitron X-ray Corp) at 2, 4, 
8, and 12 weeks post-treatment. Bridging scores were assigned to each radiograph by two 
blinded investigators where bridging was defined as continuous bone spanning the entire 
defect space (from bone end to bone end). In instances of disagreement, a third blinded 
investigator served as tiebreaker. Longitudinal bone formation was quantitatively 
evaluated using 3D micro-computed tomography (μCT) at 4, 8, and12 weeks post-
treatment. In vivo scans of the harvested femora were performed before mechanical 
testing using the vivaCT40 (Scanco Medical) at a 38 μm voxel size, 55 kVp voltage, and 
a 145 μA current. A threshold corresponding to 50% of native cortical bone density was 
applied to segment bone mineral and identify newly regenerated bone, as established 
previously [96]. The volume of interest (VOI) consisted of the central 6.46 mm (170 
slices) of the 8 mm defect. 
5.3.5 Biomechanical testing 
Torsional testing to failure was performed as previously described [96]. Femurs 
were excised at week 20 (12 weeks post-treatment), wrapped in PBS-soaked gauze, and 
stored at -20°C until testing could be performed. On the day of testing, samples were 
thawed, the surrounding soft tissues were excised, and the femora were first µCT-
scanned, as described above. Subsequently, the fixation plate was removed so that the 
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native bone ends could be potted in Wood’s metal (Alfa Aesar). The potted femurs were 
tested to failure in torsion at a rotation rate of 3° per second using the EnduraTEC 
ELF3200 axial/torsion testing system (Bose). Failure strength was determined by locating 
the peak torque within the first 60° of rotation. Torsional stiffness was calculated by 
finding the slope of the linear region before failure in the torque-rotation plot. 
5.3.6 Serum and tissue collection 
Blood was collected longitudinally via the rat tail vein at 0 (baseline), 1, 2, 4, 8, 9, 
10, 12, 16, and 20 weeks into two fractions: one for whole blood and the other for serum 
in the appropriate microvette collection tubes (Kent Scientific). For serum isolation, tubes 
were allowed to clot at room temperature for 30 minutes before storage at 4°C overnight. 
The following day, all serum tubes were centrifuged at 1500g for 10 min and the yellow 
(straw) serum was collected and stored at -20°C. The spleen, bone marrow from the left 
tibia, and muscle adjacent to the defect were all harvested at the endpoint (week 20). Red 
blood cells were lysed in all samples using 1X RBC Lysis Buffer (eBioscience) 
according to the manufacturer’s instructions. Following lysis, cells were fixed using 
Cytofix fixation buffer (BD), resuspended in FACS buffer containing 1% fetal bovine 
serum (FBS) in 1X PBS, and stored at 4˚C until staining for flow cytometry.  
5.3.7 Protein extraction for local defect tissue 
Local defect tissue was harvested at week 10 (2 weeks post-treatment) and 
immediately snap frozen using liquid nitrogen. These tissue samples were then 
homogenized in RIPA lysis buffer (Thermo Fisher Scientific) that was supplemented 
with HALT protease inhibitor cocktail (Thermo Fisher Scientific) based on 
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manufacturer’s recommended concentration. The homogenized samples were 
subsequently left on ice for at least 15 minutes before centrifugation at 13,000g for 15 
minutes. The resulting supernatant was then collected and total protein concentration was 
determined using a Pierce BCA protein assay kit (Thermo Fisher Scientific). Finally, all 
protein isolates were snap frozen and stored at -80°C until cytokine analysis by Luminex. 
5.3.8 Multivariate analysis of cytokines 
Serum isolates collected at all time points and local defect protein extracts 
collected at 2 weeks post-treatment were analyzed for cytokines via Luminex multiplex 
array (Millipore). Partial least squares discriminant analysis (PLSDA) and partial least 
squares regression (PLSR) continuous analysis was conducted in MATLAB (Mathworks) 
using the partial least squares algorithm by Cleiton Nunes (available on the Mathworks 
File Exchange). All multiplexed signaling data were z-scored, and then used as the 
independent inputs to the algorithm. An orthogonal rotation in the LV1-LV2 plane was 
used to choose a new LV1 that best separated treatment groups. 
5.3.9 Flow cytometry 
Blood was collected longitudinally via the rat tail vein at weeks 0 (baseline), 1, 2, 
4, 8, 9, 10, 12, 16, and 20 for flow cytometry analysis. The spleen, bone marrow from the 
ipsilateral tibia, and muscle adjacent to the defect were all harvested at the endpoint 
(week 20) and also analyzed by flow cytometry. Red blood cells were lysed in all 
samples using 1X RBC Lysis Buffer (eBioscience) according to the manufacturer’s 
instructions. Following lysis, cells were fixed using Cytofix fixation buffer (BD), 
resuspended in FACS buffer containing 1% fetal bovine serum (FBS) in 1X PBS, and 
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stored at 4˚C until stained. Prior to staining, cells with Fc receptors were blocked with 
purified mouse anti-rat CD32 (BD) for 10 minutes at 4˚C to prevent non-specific binding. 
Cells were then stained for various immune cell populations, including CD3
+
























), B cells (B220
+
), 
mature tissue macrophages (His36
+
), and monocytes (CD68
+
, Bio-Rad) with specific 
anti-rat antibodies (eBioscience, unless otherwise noted). Sample data was collected 
using a BD Accuri C6 flow cytometer and analyzed using FlowJo software. Gates were 
positioned based on fluorescent minus one (FMO) controls with less than 1% noise 
allowed. 
5.3.10 Statistical analyses and power calculation 
All data are reported as mean ± standard error of the mean. Significance was 
determined by t-test or analysis of variance (ANOVA) as appropriate, with multiple 
comparisons made by Tukey’s post-hoc test. Significance was determined by a p-value < 
0.05. All statistical calculations were performed using GraphPad Prism 7 software. 
Sample sizes were determined by performing a power analysis in G*Power software 
based on bone volume and maximum torque results obtained from previous studies. 
These power calculations, along with historical data using this segmental bone defect rat 





5.4.1 Early local bone defect characterization 
Cytokine expression profiles were quantified using Luminex multiplex arrays. A 
heatmap overview of cytokine expression suggested distinct profiles between groups, 
particularly for intact control femurs compared to the other groups (Figure 17A). Direct 
comparison of expression levels by 1-way ANOVA revealed differences in several 
cytokines (Figure 17B). Most notably, untreated empty defects exhibited lower 
expression of epidermal growth factor (EGF) compared to delayed and acute treatment, 
while delayed treatment demonstrated lower expression of the anti-inflammatory 
cytokine IL-4 compared to both acute treatment and empty groups. 
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Figure 17 - Cytokine expression differences in local bone defect tissue at week 10. 
Cytokine expression profiles were quantified by multiplex array (A). Comparison of 
cytokine expression by 1-way ANOVA revealed several differences (B). Most notably, 
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the empty defect group demonstrated lower expression EGF compared to both delayed 
and acute treatment, while delayed treatment exhibited lower expression of the anti-
inflammatory cytokine IL-4 compared to both acute treatment and empty. *p<0.05 as 
indicated, #p<0.05 vs Delayed and Acute, $p<0.05 vs Acute and Empty, n = 7-12/group 
 
To further evaluate the relationship between cytokine expression and healing 
response, a multivariate regression modelling approach was taken. Partial least squares 
discriminant analysis (PLSDA) of the regenerating bone defect tissue at 2 weeks post-
treatment was able to separate treatment and control groups using model-generated latent 
variables (LV) (Figure 18A). LV1 demonstrated the greatest separation between delayed 
treatment and acute/empty treatment groups. The composition of LV1 indicates that 
delayed treatment is correlated with higher expression of EGF and RANTES and lower 
expression of anti- and pro-inflammatory cytokines IL-4, MIP-1α, IL-18 and IL-6 (Figure 
18B). Intact control femurs were distinctly separated from all other groups using LV2. 
The composition of LV2 suggests that intact control samples were most highly correlated 
with expression of G-CSF, VEGF, and IFNγ, as well as most negatively correlated with 
expression of RANTES, IL-18, and MIP-1α (Figure 18B). 
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Figure 18 - Partial least squares discriminant analysis (PLSDA) of local bone defect 
cytokines. Computational regression analysis revealed separation between groups using 
latent variables (LV) (A). Cytokine composition and representation of their 
corresponding weights depict which cytokines are positively and negatively correlated 
with LV1 and LV2 (B).  
 
5.4.2 Evaluation by μCT and biomechanical testing 
Bone formation was quantified at weeks 14 and 20, corresponding to 6 and 12 
weeks post-treatment, respectively. At both time points, acute treatment demonstrated 
higher bone volumes compared to delayed treatment (Figure 19A). No differences were 
observed in bone mineral density (Figure 19B). The biomechanical strengths of the 
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regenerated femurs were assessed at week 20 by torsion testing to failure. Bone defects 
given acute treatment exhibited increased max torque (Figure 19C) and torsional stiffness 
(Figure 19D) compared to delayed treatment. Interestingly, acute treatment samples 
demonstrated lower max torque but equivalent torsional stiffness when compared to 
intact control femurs. 
 
Figure 19 - MicroCT and biomechanical evaluation of regenerated femurs. Bone 
formation was assessed by μCT for total bone volume (A) and bone mineral density (B). 
Acutely-treated defects exhibited increased total bone volume at both weeks 14 and 20 
compared to delayed treatment. No differences in bone mineral density were observed 
between treatment groups. The biomechanical strengths were determined at week 20 
through torsional testing to failure. Acutely-treated defects demonstrated increased max 
torque (C) and torsional stiffness (D) compared to defects that received delayed 




5.4.3 Longitudinal serum cytokine analyses 
Serum collected at each time point was assessed for cytokine expression using 
multiplex array. As before, a multivariate regression analysis approach was taken to 
evaluate the relationship between cytokine profile and healing response. Here, partial 
least squares regression (PLSR) was performed and cytokine expression was correlated 
with a continuous variable (amount of bone formation at week 20) rather than correlation 
with a specific treatment group (delayed vs. acute). Using this approach, we observed 
very interesting separation using LV1 where this model-generated variable seems to 
match the continuum of healing responses quite well (Figure 20A). The cytokine 
composition of LV1 indicated that greater bone formation is positively correlated with 
certain inflammatory cytokines (IL-6, LIX, IL-13, RANTES) and negatively correlated 
with others (IP-10, IL-1β, IL-10) (Figure 20B). 
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Figure 20 - Partial least squares regression (PLSR) analysis of serum cytokines. 
Computational regression of cytokine expression against bone formation at week 20 was 
able to delineate the continuum of healing responses using LV1 (A). The cytokine 
composition of LV1 suggests that greater bone formation is most strongly positively 
correlated with IL-6, LIX, IL-13, and RANTES, and most strongly negatively correlated 




5.4.4 Longitudinal circulating immune cell analyses 
At the same time points that serum collection occurred, a separate fraction of whole 
blood was processed for evaluation of circulating immune cells by flow cytometry 
(Figure 21). No significant differences between delayed and acute treatment were 
observed in any of the immune cell populations at all of the time points tested. While not 
significant, CD3+ T cells and CD4+ T helper cells appeared elevated at weeks 12, 16, 
and 20 with acute treatment, whereas circulating MDSCs appeared elevated at weeks 12, 




Figure 21 - Longitudinal assessment of circulating immune cells following 
treatment. Immune cell populations in blood were characterized by flow cytometry. No 
significant differences were observed between delayed and acute treatment. Week 8 
corresponds to baseline levels before any treatment was administered. n=8-12/group for 
each time point. 
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5.4.5 Correlation of circulating immune cells to bone healing 
To further investigate how circulating immune cells are related to the healing 
response, linear regression of the blood immune cell data was performed against bone 
formation. With this approach, we found several significant correlations. Most notably, 
there was a significant negative correlation between mean MDSC levels for each sample 
(calculated from all post-treatment time points combined) and bone formation (Figure 
22A). Interestingly, the variability in MDSCs over all post-treatment time points for each 
sample (average standard deviation) was also significantly negatively correlated with 
bone formation (Figure 22A). Analysis at each individual time point revealed a 
significant negative correlation between MDSCs and bone formation at weeks 9, 10, and 
20 (Figure 22B). Other significant correlations for individual time points include CD3+ T 
cells at week 20, CD4+ T helper cells at weeks 16 and 20, and B cells at (Supplemental?) 
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Figure 22 - Correlation of circulating MDSC populations with bone formation using 
linear regression. Both the overall mean and standard deviation in MDSC levels 
(calculated for each individual sample from all post-treatment time points) were 
significantly negatively correlated with bone formation at week 20 (A). Following 
analysis of all individual time points, MDSC levels at weeks 9, 10, and 20 were also 
significantly negatively correlated with bone formation (B). 
 
5.4.6 Analysis of additional tissues harvested at terminal time point 
At week 20, spleen, bone marrow from ipsilateral tibia, and muscle tissue directly 
adjacent to the bone defect were collected and analysed by flow cytometry. Animals that 
received acute treatment demonstrated reduced levels of CD4+ T helper cells and 
MDSCs in bone marrow compared to animals that received delayed treatment (Figure 
23). Levels of hematopoietic stem cells (HSCs) were also slightly elevated with acute 
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treatment, although not to a significant extent. No significant differences were observed 
in spleen and muscle tissues (not shown). 
 
Figure 23 - Immune cell differences in bone marrow at week 20. Immune cell 
populations in bone marrow of ipsilateral tibia were analyzed by flow cytometry. Acute 
treatment exhibited reduced levels of T helper cells and MDSCs compared to delayed 
treatment. #p<0.05 vs Delayed by student’s T test. n=8-12/group 
 
5.5 Discussion 
Immune dysfunction following severe trauma, unrelated to sepsis or multiple organ 
failure, has become fairly well-accepted by the clinical community in recent years as an 
important complication to be aware of. This has directly led to the creation of guidelines 
for the diagnosis of disorders like PICS [54]. However, this concept of persistent low-
grade inflammation and immunosuppression that subtly impairs healing has yet to be 
explored much in the context of bone injuries, including nonunion. 
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To the best of our knowledge, this work represents the first of its kind to 
demonstrate long-term immune dysfunction in a preclinical model of chronic nonunion. 
We verified that acute treatment with BMP-2 results in better healing compared to 
equivalent delayed treatment after nonunion has already been established. Using 
multivariate regression analysis methods, we found that these two treatments exhibit 
distinct expression profiles both in local bone defect tissue and in systemic blood 
circulation. Delayed treatment resulted in significantly lower early expression of the 
major anti-inflammatory cytokine IL-4, which is widely known to induce a Th2 response 
[130] and promote M2 macrophage polarization [131]. This observation potentially 
indicates a diminished initial anti-inflammatory response with treatment following 
nonunion, which may foreshadow unsuccessful resolution of the acute inflammatory 
phase and consequently lead to persistent inflammation. 
Computational regression analysis of serum cytokines implicated IL-6 and LIX as 
the cytokines most positively correlated with bone formation, whereas IP-10 was the 
cytokine that was most negatively correlated. These findings are consistent with those 
made by other groups, as IL-6 stimulates angiogenesis and promotes callus 
mineralization [132, 133] while LIX expression is necessary for IL-17-mediated 
protection from pathogenic bone destruction [134]. Interestingly, IP-10 (also called 
CXCL10) is one of the main pro-inflammatory cytokines secreted by MDSCs [135, 136]. 
Flow cytometry characterization of MDSCs in both blood and bone marrow tissues 
indicate that greater presence of MDSCs is associated with worse bone healing outcomes. 
Also, while not to a significant extent, we did observe slightly lower circulating levels of 
all T cells and CD4+ T helper cells with delayed treatment at weeks 16 and 20. Taken 
 88 
together, these results suggest that impaired bone healing in this model involves a rise in 
MDSCs that subsequently leads to a long-term reduction in effector T cell populations, 
which fit the conventional profile of PICS and chronic immune dysregulation as 
described in detail above.  
This study is not without limitations. For the systemic blood analyses in particular, 
the alterations observed in immune cell populations over time may be most influenced by 
changes due to aging rather than the response to trauma and subsequent treatment. In fact, 
immunosenescence with aging has been well-documented [137-139]. One of the 
hallmarks is an overall reduction in T and B lymphocytes as hematopoietic progenitors 
gradually favor a shift towards myeloid lineage cells, particularly pro-inflammatory 
monocytes and macrophages [140, 141]. However, many of these studies focus on age-
related immune changes from childhood to old age. In this study, all rats were 13 weeks-
old at the start and 33 weeks-old at the terminal time point, which falls well within early 
adulthood for rats and the 20 week duration of the study is relatively short considering 
the entire lifespan of rats (usually greater than 2 years). Consequently, we would expect 
age-related immune changes over the course of this study to be minimal. And yet, we still 
fully acknowledge that immune characterization of age-matched naïve animals over time 
would have been a valuable control group to confirm whether both delayed and acute 
treatment in this model actually exhibit abnormal immune variations. Despite this 
limitation, the results shown here still provide significant insight into long-term immune 
changes following treatment of nonunion and demonstrate a link between systemic 
immune health and bone healing. 
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In conclusion, this study investigated the role of immune dysregulation before and 
after treatment of nonunion. Delayed treatment was associated with changes in the local 
and systemic immune response compared to acute treatment, including lower early 
expression of anti-inflammatory cytokine IL-4 in the bone defect and higher systemic 
expression of IP-10, one of the main pro-inflammatory cytokines secreted by MDSCs. 
Additionally, increased presence of MDSCs was shown to correlate with poor bone 
healing outcomes. Further mechanistic studies are needed to validate that MDSCs are the 
main producers of the cytokines identified here, but it appears that overall, MDSCs and 
immune suppression do play a role in impaired healing after nonunion and could 
potentially be targeted in the future to improve treatment strategies. 
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CHAPTER 6. CONCLUSIONS AND FUTURE DIRECTIONS 
6.1 Primary Conclusions 
The first recorded bone grafting procedure was performed by Dr. Job van 
Meekeren in 1668, who transplanted a fragment of dog skull into the skull of a wounded 
solider [142]. In some ways, our treatment of bone injuries has not advanced much in the 
past few centuries as bone grafts, specifically autografts, remain the gold standard despite 
their known shortcomings. Bone repair involves a complex orchestration of biological 
events that is still not quite fully understood, but the influence of patient-specific factors 
has become more evident, and the need to account for these factors with more 
sophisticated treatment strategies has become increasingly apparent in recent years. 
The work presented here represents a significant contribution to the field of bone 
research by helping elucidate several factors that impact bone healing. In Aim I, the roles 
of age and dose on BMP-2-mediated bone repair were investigated. Using the current 
clinical standard BMP-2 delivered in a collagen sponge, we found that young rats were 
more responsive to increases in BMP-2 dosing compared to adult rats, without 
experiencing more complications. This is a very notable observation as BMP-2 use 
clinically is a fairly contentious topic, as it has been linked to numerous adverse events 
and is currently contraindicated for skeletally immature patients. These results indicate 
that there is an age-related dose response that should be considered when administering 
BMP-2. Taking a more conservative dosing strategy is likely to be beneficial for young 
patients and less likely to encounter unwanted complications. 
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In Aim II, we established a novel model for studying chronic nonunion by 
delaying treatment to our standard femoral bone defect. We validated that delayed 
treatment of a nounion results in impaired bone healing compared to acute treatment of a 
freshly-made bone defect, and this deficit in healing could not be overcome with a 
modest increase in BMP-2 dose. Moreover, we showed potential evidence of long-term 
immune dysregulation with delayed treatment as the non-responders (samples that did not 
demonstrated radiographic bridging) exhibited significantly higher serum expression of 
TNFα and IL-1β compared to responders at week 20, suggestive of a prolonged 
inflammatory state. 
Finally, in Aim III we performed much more in-depth characterization of the 
immune profiles in the chronic nonunion model. Early local defect tissue analysis 
revealed reduced local IL-4 expression with delayed treatment, possibly indicative of a 
diminished anti-inflammatory response after nonunion that will be insufficient to resolve 
acute inflammation. Furthermore, systemic evaluation of immune cells in blood and bone 
marrow established a link between increased MDSC presence and impaired bone healing. 
This observation was supported by serum cytokine analyses, which implicated a major 
cytokine produced by MDSCs, IP-10, as being strongly negatively correlated with bone 
formation. Overall, these results provide mounting evidence that long-term immune 
dysregulation is involved during nonunion, and that MDSCs may be one of the main 
drivers of chronic immune suppression that develops even after treatment. Both of these 
conclusions are novel contributions that motivate further research into the dynamics 
between immune dysfunction and nonunion. 
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6.2 Future Directions 
The body of work shown here represents just one of many examples found 
throughout literature that support the importance of immune cells during normal bone 
repair. While prolonged inflammation is detrimental to healing, disrupting the initial 
acute inflammatory response by depleting certain immune cell populations can be equally 
as destructive. Seminal work by Godwin et al. demonstrated that knocking out 
macrophages completely abrogated normal limb regeneration in axolotls [143]. Nam et 
al. observed deficits in early osteogenic expression in a Rag1-/- murine model that lacks 
mature T and B cells compared to wild type mice [144]. Interestingly, a separate group 
utilizing the same Rag1-/- mouse actually found improved fracture healing compared to 
wild type mice [145]. This same group has since demonstrated inhibition of bone healing 
by a subset of CD8+ effector memory T cells [146]. These seemingly contradictory 
findings point to the complexity of the immune response during bone healing, and 
suggest that the roles that immune cells play are highly context and time-dependent. 
Regardless, all of these studies promote the idea that modulating the immune response 
can potentially enhance bone healing and lead to the discovery of new therapies. 
Unfortunately, there have not been any documented successful therapies to combat 
long-term immune dysfunction such as in PICS, perhaps due in part to under-recognition 
of PICS as its own distinct phenotype from more well-established syndromes like MODS 
[53]. Nonetheless, chronic immune dysregulation remains an important concern for 
patients recovering from severe trauma, and certain immune cell populations, particularly 
Tregs and MDSCs, have drawn considerable interest from the scientific research 
community [135, 147]. Osteoimmunology is a rapidly emerging field that seems like the 
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prime candidate for tackling some of these challenges, yet it has primarily focused on the 
interactions between immune and skeletal systems in the context of diseases such as 
rheumatoid arthritis [148], cancer [149], osteoporosis [150], and certain autoimmune 
disorders [151]. Consequently, many questions remain about the interplay between these 
two complex systems following traumatic injury, and the importance of restoring long-
term immune homeostasis on bone regeneration requires further investigation. 
In that regard, the prospect of immunomodulation to improve bone repair remains 
an exciting possibility. Immunotherapies have been explored in recent years to treat a 
wide range of diseases including neurodegenerative disorders [152], HIV/AIDS [153], 
and most notably cancer [154]. The applications of immunomodulation to bone repair are 
not nearly as advanced comparatively, and have thus far mainly focused on the 
endogenous immunomodulatory capabilities of mesenchymal stem cells [155, 156] or the 
direct delivery of immunomodulatory cytokines [157, 158]. An idea that has gained 
traction within the orthopedic community is the importance of macrophages during bone 
repair. This is not surprising considering it is well-established that osteoclasts and 
macrophages share a common lineage, and it has even been shown that there are unique 
resident macrophages in bone [159]. A few groups have recently tried to promote 
osteogenesis by activating specific macrophage phenotypes [160, 161], but only in vitro 
or in heterotopic in vivo models. Nevertheless, these studies represent clear advancements 
in the field yet also demonstrate that there is much progress to be made in the 
development of more targeted immunomodulatory therapies for bone repair. 
The results from this work, specifically the findings in Aim 3, motivate the 
targeting of certain immune cell types for bone repair. The Roy lab at Georgia Tech has 
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previously developed immunomodulating microparticles that can stimulate dendritic cells 
and alter their secretome [162]. Perhaps a similar approach could be taken to either 
inhibit immune suppressive cells such as MDSCs or augment positive immune effector 
cells as a means of improving healing in our model of chronic nonunion. Successful 
inhibition of MDSCs has actually been shown to enhance the effectiveness of cancer 
immunotherapies in treating tumors [77]. One could imagine that a combinatorial strategy 
that both rejuvenates the immune system to combat chronic immunosuppression as well 
as treats the primary traumatic injury will result in better regenerative outcomes than 
either single therapy alone. Another approach that could be taken would be to focus more 
broadly on the balance in overall Th1/Th2 response and the relative polarization of 
M1/M2 macrophages. Indeed, several groups have already started down this path and 
have demonstrated some promising results for repair of bone and other associated tissues 
[161, 163-167]. 
The major underlying theme of this thesis is that better understanding of patient-
specific factors will potentially lead to better treatment strategies for bone repair. Many 
of these factors, such as age, gender, presence of co-morbidities, lifestyle choices, and 
diet are already widely accepted to have an impact on healing. Yet very rarely are these 
factors taken into account when implementing a bone healing treatment strategy. In Aim 
I, we demonstrated that adjusting something as simple as dose could be very beneficial 
for current BMP-2 therapies, particularly for the pediatric population for whom all BMP-
2 use is contraindicated. Recently, technological advances have made genomic 
sequencing exponentially faster and much more affordable to the general public, and 
genetic testing has become much more widespread throughout all areas of healthcare. In 
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the context of bone injuries and diseases, there is some early evidence of a genetic 
predisposition towards poor healing outcomes such as nonunion [168-170]. 
Ultimately, the goal of characterizing the multifactorial problem that is bone repair 
would be to develop predictive models that can help guide the design of more 
personalized treatment strategies in order to achieve the best possible outcome for each 
patient. The results presented here demonstrate the potential value of monitoring specific 
noninvasive biomarkers following treatment, such as circulating cytokines and immune 
cells. Indeed, many groups have begun looking into various biomarkers and immune cell 
quantification as a means of predicting mortality, sepsis, and other complications 
following trauma and surgery [69, 171-173]. In the context of bone healing, Pountos et al. 
recently compiled a review of relevant biomarkers that have potential predictive power 
for fracture nonunion, including serum ALP and TGFβ1 levels [174]. For all of these 
predictive models though, it is important not to overstate the predictive power of 
biomarkers found in preclinical models and their applicability to human patients. This 
issue was highlighted recently in conflicting high impact publications that investigated 
the relevance and utility of murine models for the study of human inflammatory diseases 
[175, 176]. Nevertheless, our work provides substantial evidence of noninvasive 
biomarkers being highly correlated (both positively and negatively) with bone healing 








Bone morphogenetic protein 2 (BMP-2) loaded collagen sponges remain the 
clinical standard for treatment of large bone defects when there is insufficient autograft, 
despite associated complications. Recent efforts to negate co-morbidities have included 
biomaterials and gene therapy approaches to extend the duration of BMP-2 release and 
activity. In this study, we compared the collagen sponge clinical standard to chondroitin 
sulfate glycosaminoglycan (CS-GAG) scaffolds as a delivery vehicle for recombinant 
human BMP-2 (rhBMP-2) and rhBMP-2 expression via human BMP-2 gene inserted into 
mesenchymal stem cells (BMP-2 MSC). We demonstrated extended release of rhBMP-2 
from CS-GAG scaffolds compared to their collagen sponge counterparts, and further 
extended release from CS-GAG gels seeded with BMP-2 MSC.  When used to treat a 
challenging critically-sized femoral defect model in rats, both rhBMP-2 and BMP-2 MSC 
in CS-GAG induced comparable bone formation to the rhBMP-2 in collagen sponge, as 
measured by bone volume, strength, and stiffness. We conclude that CS-GAG scaffolds 
are a promising delivery vehicle for controlling the release of rhBMP-2 and to mediate 
the repair of critically-sized segmental bone defects. 
2
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and recombinant protein-based bone regeneration. Under review in Journal of Tissue Engineering 




Bone tissue is well known for its remarkable healing abilities, but there are 
instances in which these mechanisms are insufficient on their own. Large defects or gaps 
in bone are unable to be bridged without intervention. Allografts and autografts are 
popular bone grafting methods, accounting for over 2 million procedures per year [177]. 
However, these procedures are not devoid of complications. Autografts, which are 
derived from the patient themselves, are the current gold standard, but are the most 
difficult to obtain and have the risk of donor site morbidity [178, 179]. Allografts, from 
other individuals of the same species, are more likely to be rejected, require lifelong 
immunosuppression, and are potential sources of disease transmission [178, 180, 181]. 
Due to these issues, there have been numerous attempts to develop new synthetic bone 
graft substitutes to enhance bone healing.  
Bone Morphogenetic Protein 2 (BMP-2) is an osteoinductive growth factor 
commonly used in bone substitute applications. It usually exists as a homodimer, binding 
to serine/threonine kinase receptors to initiate endocrine, paracrine, and autocrine effects 
[182, 183]. The recombinant human BMP-2 (rhBMP-2) is FDA-approved, and used 
clinically in combination with a collagen sponge. It has been shown to reduce the rate of 
secondary intervention and enhance fracture healing, and has shown additional benefits 
for many orthopedic applications [184, 185]. Thus any new modality for treating 
critically-sized bone defects should undergo a rigorous investigation with comparison to 
current FDA approved techniques, such as rhBMP-2 on collagen sponge.  
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Despite its well documented ability to induce bone formation, rhBMP-2 has a very 
short half-life, leading to the use of supraphysiological doses by clinicians [186, 187].  
Complications associated with delivery of rhBMP-2 clinically have been reported to 
include ectopic bone formation, inflammation, and increased cancer rates among patients 
[11, 188]. Additionally, the large amount of recombinant protein required for this 
approach leads to increased costs compared to alternative treatments  [189]. In rats, 
clinically relevant doses of rhBMP-2 have been shown to induce the formation of 
structurally abnormal bone, as well as inflammation [89]. These drawbacks could be 
addressed by using a delivery method with sustained release of a lower dose of BMP-2.  
One such delivery system could involve use of constitutive BMP-2 expression via 
genetically engineered mesenchymal stem cells (MSCs) for BMP-2 delivery (BMP-2 
MSC) [190-193].  
MSCs are multipotent stromal cells commonly studied and used for their ability to 
differentiate into bone, cartilage, and adipose tissue [194]. They are attractive as a 
delivery mechanism due to their ease of collection and expansion from bone marrow, 
adipose, and umbilical tissue, as well as their immune modulation capabilities and 
allogeneic tolerability. Osteogenic differentiation can be readily induced in MSCs, even 
in the absence of BMP-2 and transforming growth factor β1 (TGF-β1) signaling [195]. 
Our group has previously demonstrated success in creating ectopic bone, and 
regenerating critically-sized defects in rats using BMP-2-expressing MSCs encapsulated 
in poly-ethylene glycol (PEG) microspheres [196, 197]. However, these studies noted a 
sharp decrease in encapsulated cell viability after 4 days [196]. PEG has been shown to 
be safe for implantation but it is not inherently osteoconductive or biodegradable without 
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further modifications [198, 199].  In addition, PEG cell encapsulation procedures can be 
labor intensive, variable, and inefficient [200].  
Chondroitin sulfate glycosaminoglycans (CS-GAGs) are found attached to CS 
proteoglycans in the extracellular matrix of cartilage, bone, and other tissues. They are O-
linked glycans consisting of repeating glucuronic acid and N-acetylgalactosamine 
disaccharides. CS-GAGs are important for bone development as they can support 
osteogenesis and suppress bone resorption [195, 201-204]. Additionally, they regulate 
both TGF-β1 and BMP signaling in bone, and have been shown to retain TGF-β [195, 
205]. In other studies, sulfated glycosaminoglycans assisted in BMP-2’s interaction with 
its receptor, and oversulfated chondroitin sulfate enhanced osteoblast mineralization in 
the presence of BMP-4 [206, 207]. These qualities lend themselves to the use of CS-
GAGs as a scaffold for the slow release of BMP-2. 
In this study, we describe an injectable biologic therapy for large bone defect 
healing. It consists of human MSCs genetically engineered to overexpress BMP-2, which 
are then seeded in a CS-GAG gel. We demonstrated high levels of BMP-2 expression in 
BMP-2 MSCs, maintained viability post-seeding, and sustained in vitro BMP-2 release 
from this system compared to BMP-2 on collagen sponge. Additionally, we show the 
formation of comparable bone quantity and quality to the clinical standard in a rigorous 
rodent critically-sized segmental defect model. These results indicate the potential of this 
system to be a valuable therapeutic option for healing large bone defects. 
Materials and Methods 
Cell Culture and Transduction 
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Human umbilical (uMSC) or bone marrow MSCs (bmMSC), (Lifeline Cell 
Technology, Frederick MD, Sciencell, Carlsbad CA) were plated at 5000 cells/cm
2
 on 
tissue culture flasks in complete media Alpha-Minimum Essential Medium (MEM-α), 
10% defined fetal bovine serum (Hyclone, South Logan UT), 2 mM L-glutamine, 50 
U/mL penicillin, 50 μg/mL streptomycin and allowed to grow to 80-90% confluency 
(20,000–25,000 cells/cm
2
).  To transduce, cells were harvested using 0.05% trypsin and 
plated at 26,000 cells/cm
2
 in MEM-α, 10% defined fetal bovine serum, 5 μg/mL 
Polybrene (Sigma-Aldrich, St. Louis MO), and the appropriate MOI of prEF1a-BMP-2 or 
prEF1a-RFP lentivirus (Cellecta, Mountain View CA) on tissue culture flasks. The media 
was changed back to complete media 24 hours post-transduction. All cultures were 
maintained at 37°C and 5% CO2, and used up to twenty passages. All materials were 
from Invitrogen (Carlsbad CA) unless otherwise stated.  
In vitro RFP expression 
Following transduction of uMSCs with the prEF1a-RFP vector in MOIs of 0, 1, 
10, and 50 as described above, both phase contrast and fluorescent images were taken. 
Five images per well and three wells per condition were taken at 24, 48, and 72 hours 
post-transduction. 
In vitro BMP-2 expression 
Following transduction of uMSCs with the prEF1a-BMP-2 vector in MOIs of 10 
and 50 as described above, 0.5 mL media samples were collected in triplicate from 
different sets of wells at 48, 72, 96 and 120 hours post-transduction. BMP-2 
concentrations were determined via BMP-2 ELISA (R&D Systems, Minneapolis MN). 
 101 
Hydrogel Preparation and Characterization 
Rheological testing and Scanning Electron Microscopy (SEM) were used as 
previously described to characterize the CS-GAG hydrogels. Briefly, hydrogel mixture 
was prepared by reconstituting 3% w/v of lyophilized methacrylated chondroitin sulfate 
and 0.01% 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure-2959, 
Sigma-Aldrich, St. Louis MO) in PBS.  
Rheological testing of the hydrogel was performed as described previously [208]. 
Briefly, 500 µL of the hydrogel mixture was dispensed into a polydimethylsiloxane mold 
overlaid onto a glass slide, and exposed to 365 nm long-wavelength UV light (160 W 
BlakRay, UVP, Upland CA) for 3 min to yield hydrogel disks 1 in. in diameter and 6 mm 
thick. The hydrogels were then overlaid with 1 mL of PBS to swell overnight before 
rheological testing, which was performed on an ARES rheometer (TA Instruments, New 
Castle DE), using a parallel plate geometry. Frequency sweep experiments from 0.1 to 
100 Hz were performed at 5% strain at 25°C. 
Morphology of gold coated lyophilized hydrogel samples was examined as 
described previously using a Zeiss 1450EP SEM scanning electron microscope (Carl 
Zeiss, Oberkochen Germany) [208]. Briefly, hydrogels were flash frozen in liquid 
nitrogen and lyophilized. They were then mounted on 10 mm SEM stubs and sputter 
coated (Structure Probe Inc., West Chester PA) with gold for 30 s, and imaged under an 
accelerated voltage of 5 kV. Images were acquired at 165x and 500x to observe the 
porosity and microstructure of the hydrogels. 
Cell Seeding 
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Following casting as described above, 500 µL gels were frozen overnight at -
80°C, after which they were lyophilized for 24 hours (Fig. 3A). To rehydrate them, the 
lyophilized hydrogels were overlaid with either a 6.66x10
6
/mL cell suspension 
(GAG+MSC or GAG+BMP-2 MSC) or 33.3 μg/mL rhBMP-2 (GAG+rhBMP-2) of equal 
volume to the gel in MEM-α and allowed to incubate at 37°C and 5 % CO2 until all free 
liquid was absorbed into the gel. The hydrogel was then transferred to a sterile 1cc 
syringe, pulse centrifuged to remove air pockets and injected/ejected with a sterile 22G 
needle. 
Viability and Distribution 
24 hours after transduction with the prEF1a-RFP vector at MOI 10, uMSCs were 
seeded in CS-GAG hydrogels and overlaid with 2 μM Calcein in PBS. Cells were imaged 
using FITC and TRITC fluorescent filters 3 hours after seeding. Viability of transduced 
cells was determined by quantifying the degree of fluorescence overlap of RFP and 
Calcein using the Mander’s overlap co-efficient parameters in Volocity (PerkinElmer, 
Waltham MA) as described previously. 
Nanofiber mesh fabrication 
Perforated nanofiber mesh tubes were fabricated as described previously [98]. A 
12% (w/v) solution of poly(ε-caprolactone) (PCL) was made by dissolving PCL (Sigma-
Aldrich, St. Louis MO) in a 90:10 mixture of hexafluoro-2-propanol:dimethylformamide 
(Sigma-Aldrich, St. Louis MO). The solution (~4mL) was electrospun onto a static 
collector plate to obtain PCL sheets. Rectangular sections (12x19 mm) containing twenty 
three 1-mm-diameter circular holes were then cut using a VLS3.50 laser cutter (Universal 
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Laser Systems, Scottsdale AZ). Each rectangular piece was then rolled up into a 
cylindrical tube (5 mm diameter, 12 mm in length) and glued using medical grade UV-
curable adhesive (Dymax, Torrington CT). Meshes were sterilized by ethanol 
evaporation, washed and stored in PBS, and then transferred to MEM-α and stored at 4°C 
prior to use. 
Preparation of GAG treatment groups 
One day prior to surgery/experiment, uMSCs were either left non-transduced or 
transduced at 10 MOI and seeded in CS-GAG hydrogels 24 hours after transduction as 
described above. On the day of surgery/experiment, rhBMP-2 (R&D Systems, 
Minneapolis MN) was reconstituted according to the manufacturer’s instructions, diluted 
to 33.3 ug/mL in MEM-α, and used to rehydrate lyophilized CS-GAG hydrogel as 
described above.  
Collagen sponge preparation 
The day before each surgery/experiment, rhBMP-2 (Pfizer Inc., New York, NY) 
in 0.1% rat serum albumin (Sigma-Aldrich, St. Louis MO) in 4 mM HCL solution was 
made up to a concentration of 33.3 ug/mL and then stored at 4°C overnight. Collagen 
sponge cylinders ~5mm in diameter and 10mm in length were created by biopsy 
punching out from a sheet of bovine collagen sponge (Kensey Nash/DSM, Exton PA). 
All collagen sponge cylinders were sterilized by ethylene oxide. Prior to the start of the 
surgery/experiment, the collagen sponge cylinders were transferred to a 24-well plate, 
and then 150 μl of the rhBMP-2 solution was slowly loaded onto each cylinder. The 
sponges were left to sit for ~10 minutes to soak up any residual rhBMP-2 solution in the 
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well before being carefully transferred to another well plate for in vitro release 
characterization or press-fit into the bone defect for in vivo studies 
Hydrogel BMP-2 Release 
Experimental groups were prepared as follows: CS-GAG hydrogels were 
rehydrated with 6.67x10
6
 cells/mL non-transduced uMSCs (GAG+MSC), transduced 
uMSCs (GAG+BMP-2 MSC), or 3.33 μg/mL rhBMP-2 (GAG+rhBMP-2), and 150 μL of 
each rehydrated gel was injected into polycaprolactone (PCL) nanofiber meshes and 
placed into individual wells of an ultra-low adhesion 24-well plate (Nunclon Sphera, 
ThermoFisher, Waltham MA). For the collagen sponge group (Col+rhBMP-2), 150 μL of 
3.33μg/mL rhBMP-2 solution was loaded onto each sponge and each sponge was then 
placed into an individual well of the 24-well plate (without any PCL mesh). 
For the release experiment, 1 mL of MEM-α only were added to each well. All 
scaffolds were then allowed to incubate at 37°C and 5 % CO2. At 3 h, 12 h, 1, 2, 3, 5, 7, 
9, 11, and 13 days, the overlaid media were collected and immediately stored at -80°C, 
and the extracted media was replaced with 1 ml of fresh media. On day 15, media were 
collected and then replaced with 1 ml of digest solution. The CS-GAG hydrogels were 
digested with 1 ml media containing 20 mU of chondroitinase ABC (Sigma-Aldrich, St. 
Louis MO) while the collagen sponges were digested with 1 mg/ml collagenase type I 
(Sigma-Aldrich, St. Louis MO).  Digestion occurred for 24 hours at 37°C before 
collection and storage at -80°C as before. BMP-2 ELISA was performed on the collected 
media to determine the amount of BMP-2 released from the scaffolds at each timepoint. 
Segmental defect surgery 
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The surgical procedure has been described previously [96]. Briefly, an 
anterolateral skin incision was made in the leg, and then blunt dissection was performed 
to allow for placement of a polysulfone fixation plate. Critically-sized 8 mm defects were 
created in the mid-diaphysis of the femur using an oscillating saw. The desired 
therapeutic was then delivered to the defect site, and finally the muscle and skin were 
closed using 4-0 vicryl suture (Ethicon, Somerville NJ) and wound clips, respectively. 
Prior to surgery, all animals were given a subcutaneous injection of slow-release 
buprenorphine for analgesia and anesthesia was induced using isoflurane. For all 
experiments, 14-week-old female RNU Nude rats (Charles River Laboratories, 
Wilmington MA) were used.  
Radiography and microcomputed tomography 
To qualitatively assess longitudinal bone regeneration, 2D in vivo radiographs 
were taken using the MX-20 digital machine (Faxitron X-ray Corp, Tucson AZ) at 2, 4, 
8, and 12 weeks post-surgery. Radiographs were acquired using an exposure time of 15 
seconds and energy at 25 kV. Bridging scores were assigned to each radiograph by two 
blinded investigators where bridging was defined as contiguous bone spanning the entire 
defect space (from bone end to bone end). In instances of disagreement, a third blinded 
investigator served as tiebreaker. 
New bone formation was quantitatively evaluated using 3D microcomputed tomography 
(μCT) at 12 weeks post-surgery. Scans were performed using the vivaCT40 (Scanco 
Medical, Brüttisellen Switzerland). Ex vivo scans were performed at a 21 μm voxel size, 
55 kVp voltage, and a 145 μA current. The volume of interest (VOI) consisted of the 
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central 6.36 mm (303 slices) of the defect. A threshold corresponding to 50% of native 
cortical bone density was applied to segment bone mineral [209]. 
Mechanical testing 
Torsional testing to failure was performed as previously described [96]. Femurs 
were excised at 12 weeks post-surgery, wrapped in PBS-soaked gauze, and stored at -
20°C until testing could be performed. On the day of testing, samples were thawed in a 
beaker of tap water, the surrounding soft tissues were excised, and the fixation plate was 
removed so that the native bone ends could be potted in Wood’s metal (Alfa Aesar, 
Haverhill MA). Potted femurs were then rotated at a rate of 3 degrees per second until 
failure using the EnduraTEC ELF3200 axial/torsion testing system (Bose, Framingham 
MA). Failure strength was determined by locating the failure (peak) torque within the 
first 60° of rotation. Torsional stiffness was calculated by finding the slope of the linear 
region before failure in the torque-rotation plot. 
Statistical Analysis 
Unless otherwise noted, all data were analyzed via nonparametric Kruskal-Wallis 
test with multiple comparisons made by Dunn’s post-tests as appropriate using GraphPad 
Prism software. Significance was determined as p < 0.05. 
Results 
MSC transduction 
Fluorescence microscopy of pr-EF1a-RFP lentivirus transduced uMSCs 
qualitatively showed transduction efficiency at 24, 48, and 72 hours post-transduction. 
 107 
Visual transduction efficiency approached 100% at 10 and 50 MOI (Fig. 1A). BMP-2 
ELISA of media collected from pr-EF1a-BMP2 lentivirus transduced MSCs at 48, 72, 96, 
and 120 hours post-transduction assessed rhBMP-2 production in both uMSCs and 
bmMSCs at 10 and 50 MOI (Fig. 1B). Non-transduced MSCs expressed BMP-2 below 
the detection threshold of the ELISA kit used and are not shown. All transductions 
resulted in greater amounts of rhBMP-2 released over time. By 96 and 120 hours post-
transduction, significantly more BMP-2/cell was produced at both 10 and 50 MOI in 
uMSC than bmMSC. However, there was no significant difference between 10 and 50 
MOI for either cell type. 
 
Figure 24 - Efficient transduction of uMSCs with a lentiviral vector at 10 MOI.    
(A) Images of uMSC over 72 hours after transducing with prEF1a-RFP at 10 and 50 MOI 
under phase contrast and RFP filter to evaluate transduction efficiency. Scale bars 
indicate 200 µm. N = 15. (B) Mean BMP-2 expression in uMSCs and bmMSCs at 48, 72, 
96, and 120 hours after transducing with prEF1a-BMP2 at 10, and 50 MOI, comparing 
expression over cell type and MOI within each time point. Transductions at 0 MOI did 
not result in BMP-2 expression detectable by BMP-2 ELISA. Significant differences 
from uMSC 10 MOI (*,**) and 50 MOI (#,##) at p<0.05 and 0.01 respectively. Error 





CS hydrogel characterization 
The 3% CS hydrogels were transparent and porous (Fig. 2A), with pores ranging 
between 20-100 μm in diameter. The hydrogel storage modulus ranged between 350 and 
450 Pa, increased at higher frequencies indicating strain hardening, and demonstrated 
nonlinear elasticity that is typical of biological materials (Fig. 2B) (6).  
 
Figure 25 - CS-GAG hydrogel is porous with stable rheology. (A) Scanning electron 
microscopy of CS gel surface at 165x magnification. Pore sizes are about 20-100 µm. 
Scale bars indicate 500 µm and 100 µm respectively. (B) Rheology of CS-GAG gel. Data 
indicate stable rheological properties across a range of frequencies. Error bars indicate 
standard error (n=5). 
 
Transduced MSC Viability and Distribution in CS hydrogels 
Viable transduced MSCs were identified via colocalization of RFP and Calcein 
AM. Seeded MSCs were distributed homogeneously, and showed colocalization of RFP 
and Calcein in the cytoplasm. Mean values and standard error of Pearson’s Correlation 
and Colocalization Coefficients M1 and M2 were 0.88± 0.01, 0.94 ± 0.01, and 0.85 ± 
0.02, respectively, indicating approximately 85-88% viability in seeded cells (Fig 3B).  
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Figure 26 - Preparation of CS-GAG hydrogel and interactions with transduced 
MSCs. (A) Casting of 3% GAG hydrogel (i) followed by photo crosslinking under UV 
light (ii). The hydrogel is lyophilized for 24 hours (iii) before it is rehydrated with a cell 
suspension in basal media (iv). (B) Measures of colocalization for calcein and RFP: 
Pearsons Correlation, describing the extent of overlap between RFP and calcein images, 
and Colocalization Coefficients M1/M2, describing the fraction of RFP colocalizing with 
calcein, and the fraction of calcein localizing with RFP, respectively (n=5). (C) 
Cumulative BMP-2 release over 15 days from empty GAG gels, GAG gels loaded with 1 
million non-transduced MSCs, and GAG gels loaded with 1 million BMP-2 MSCs (n=3-
4). (D) BMP-2 release kinetics shown as percentage of the total amount released for 
GAG gels loaded with BMP-2 MSCs, as well as GAG gels and collagen sponges loaded 
with rhBMP-2 (n=3-4). 
 
Quantification of BMP-2 release 
BMP-2 MSC in GAG hydrogel secreted over 7 µg of BMP-2 cumulatively over 
the course of 16 days in vitro, which was over 1000x higher than the release from non-
transduced MSCs in GAG in the same time period (Fig. 3C). Furthermore, comparison of 
the release kinetics to exogenous delivery of rhBMP-2 revealed that Col+rhBMP-2 had 
the highest initial burst release of BMP-2, followed by GAG+rhBMP-2, and GAG+BMP-
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2 MSC having the slowest BMP-2 release profile (Fig. 3D). The time taken to release 
50% of the total BMP-2, was approximately Day 1.5, Day 5, and Day 9 for Col+rhBMP-
2, GAG+rhBMP-2, and GAG+BMP-2 MSC, respectively. 
 
Bone defect bridging 
Radiographs qualitatively showed progressive mineralization from 4 to 12 weeks 
in the GAG+BMP-2 MSC, GAG+rhBMP-2, and Col+rhBMP-2 groups (Fig. 4B). Defect 
bridging was determined from the radiographs after 12 weeks, and the bridging scores for 
each group were 0/7 for GAG+MSC, 4/7 for GAG+BMP-2 MSC, 6/8 for GAG+rhBMP-
2, and 7/8 for Col+rhBMP-2. These two-dimensional assessments of defect bridging were 
verified using three-dimensional µCT reconstructions as well (Fig. 4C). 
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Figure 27 - Bone defects bridge when treated with rhBMP-2 or BMP-2 MSCs.      
(A) Illustration of rat femoral defect model with an internal fixation plate and delivery of 
gel into the perforated holes of the PCL nanofiber mesh. (B) Representative longitudinal 
radiographs at 4 and 12 weeks post-surgery. Defects were treated with 1 million non-
transduced uMSCs in 150 μLCS-GAG gel, 1 million BMP-2 uMSCs in 150 μLCS-GAG 
gel, 150 μL CS-GAG hydrogel loaded with 5 μg rhBMP-2, or 150 μL collagen sponge 
loaded with 5 μg rhBMP-2. (C) 12-week μCT reconstructions of the same bone defects 
shown in the radiographs. 
 
Bone formation quantification 
µCT analysis showed mean total bone volumes of 2.81, 42.91, 44.52 and 39.70 
mm
3
, respectively, in the GAG+MSC, GAG+BMP-2 MSC, GAG+rhBMP-2, and 
Col+rhBMP-2 groups at 12 weeks (Fig. 5A).  Bone volumes in the GAG+MSC group 
were significantly lower than that of the other three groups. There were no significant 
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differences in bone volume among GAG+BMP-2 MSC, GAG+rhBMP-2, and 
Col+rhBMP-2. Interestingly, when polar moment of inertia (pMOI) was calculated to 
assess the spatial distribution of the newly formed bone (Fig. 5B), both GAG+BMP-2 
MSC and GAG+rhBMP-2 groups had significantly higher average pMOI compared to 
GAG+MSC, while Col+rhBMP-2 did not. 
 
Figure 28 - Newly-formed bone similar between rhBMP-2 and BMP-2 MSC groups. 
µCT characterization and mechanical testing of regenerated femurs at 12 weeks. (A) 
Quantification of new bone revealed GAG+BMP-2 MSC, GAG+rhBMP-2, and 
Col+rhBMP-2 all demonstrated greater total bone volumes than GAG+MSC. (B) 
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Calculated average polar moment of inertia (pMOI) showed both GAG+BMP-2 MSC 
and GAG+rhBMP-2 groups had significantly higher pMOI compared to GAG+MSC. (C) 
Torque to failure and (D) torsional stiffness measured from testing regenerated femurs to 
failure at 12 weeks. Both GAG+rhBMP-2 and Col+rhBMP-2 groups had significantly 
higher torque to failure and torsional stiffness compared to GAG+MSC. There were no 
significant differences between GAG+BMP-2 MSC, GAG+rhBMP-2, and Col+rhBMP-2 
for any of these metrics. Error bars indicate standard error (n=7-8/group). 
 
Biomechanical testing 
The mean failure torques were 0.0066, 0.1250, 0.1465 and 0.1774 N-m, 
respectively, in the GAG+MSC, GAG+BMP-2 MSC, GAG+rhBMP-2, and Col+rhBMP-
2 groups at 12 weeks (Fig. 5C). The mean torsional stiffnesses were 0.00009, 0.0149, 
0.0159 and 0.0197 N-m/deg, respectively, in the GAG+MSC, GAG+BMP-2 MSC, 
GAG+rhBMP-2, and Col+rhBMP-2 groups (Fig. 5D). For both parameters, only the 
GAG+rhBMP-2 and Col+rhBMP-2 groups had significantly higher values compared to 
GAG+MSC. However, there were no significant differences among GAG+BMP-2 MSC, 
GAG+rhBMP-2, and Col+rhBMP-2 groups. 
Histology 
H&E staining demonstrated clear morphological differences between the three 
BMP-2 groups and the GAG+MSC group (Fig. 6). In the GAG+MSC samples, there was 
very little new bone formation and instead, the defect was filled with mostly soft, fibrous-
like tissue with extensive cell infiltrate. In contrast, the GAG+BMP-2 MSC, 
GAG+rhBMP-2, and Col+rhBMP-2 groups all showed distinct islands of new bone 
formation that were surrounded by marrow-like material. In the Col+rhBMP-2 group in 
particular, this marrow-like material appeared less dense and much more disperse. When 
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viewed under polarized light, the collagen of the new bone in the Col+rhBMP-2 group 
appeared much more aligned (bright pink), indicative of lamellar structure, whereas the 
new bone in both GAG+BMP-2 MSC and GAG+rhBMP-2 groups had more disorganized 
collagen, suggestive of woven bone morphology. 
 
Figure 29 - Histology reveals qualitative differences in bone maturity. H&E staining 
of defect tissue viewed under polarized light. All BMP-2 groups exhibited islands of new 
bone formation while GAG+MSC did not. Furthermore, upon inspection under polarized 
light to assess collagen alignment, the bone in the Col+rhBMP-2 group appeared to be 
predominantly lamellar in structure whereas both GAG+BMP-2 MSC and GAG+rhBMP-
2 had material resembling woven bone. 
 
Discussion  
The complex milieu of cells, soluble factors and extracellular matrix at the bone 
defect site is largely unexplored. However, treatment with substantial doses of rhBMP-2 
at orthotopic sites can lead to robust bone healing. Given the complications that can arise 
from high dose bolus rhBMP-2 treatment, alternative controlled delivery strategies have 
been sought, comprising cell and gene-based therapies within biomaterial carriers. Indeed 
rhBMP-2 genetically-engineered MSCs have been shown to promote bone regeneration 
in a rat calvarial bone defect [210] and in mandible distraction surgery in dogs [211]. In 
previous studies, polymer scaffolds coated with adeno-associated viral vector encoding 
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rhBMP-2 successfully bridged about 50% of rat femoral defects at 12 weeks without 
ectopic bone formation [212], and low dose sustained rhBMP-2 expression was achieved 
by PEG-encapsulated rhBMP-2 expressing MSCs [197]. In the latter case, the use of a 
CS-GAG hydrogel could present additional advantages with sulfated CS-GAGs 
promoting rhBMP-2 stabilization as demonstrated previously [206], and as discussed in 
our findings here.   
In this study, we compared the collagen sponge clinical standard to CS-GAG as a 
delivery vehicle for recombinant human BMP-2 (rhBMP-2) and rhBMP-2 expression via 
rhBMP-2 gene inserted into mesenchymal stem cells (BMP-2 MSC). Since the lentiviral 
system is able to integrate into the host cell genome, MSCs were transduced with a 
lentiviral vector to express high levels of rhBMP-2, with MSCs sourced from umbilical 
tissue expressing at a higher level than those from bone marrow. Most previous studies 
have used bone marrow MSCs, but Mizrahi et al showed similar efficiency of BMP 
overexpression between bone and adipose-derived MSCs [192, 213-215]. Compared to 
previous studies using adenovirus or nucleofection, lentiviral transduction induced a 
higher expression of BMP, and greater bone formation in vivo [197, 216, 217].  Our 
comparisons between adeno- and lentiviral transduction within the same MSC population 
(not shown) corroborate these findings, prompting us to implant far fewer cells (only 1 
million BMP-2 MSCs per defect) than similar studies.   
The characterization of the in vitro rhBMP-2 release profiles permitted greater 
insights into the potential differences in bone regeneration in vivo. Of the three rhBMP-2 
treatment groups tested (GAG+BMP-2 MSC, GAG+rhBMP-2, and Col+rhBMP-2), 
Col+rhBMP-2 demonstrated the fastest initial burst release while GAG+BMP-2 MSC 
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exhibited the slowest, most sustained release. These in vitro observations were partially 
reflected in the spatial distribution of newly formed bone in vivo, as the GAG+BMP-2 
MSC group had the highest average pMOI, indicative of bone formation that is more 
disperse and peripheral. These results are in-line with findings from other groups, which 
have shown that the timing of rhBMP-2 expression/release greatly influences the 
distribution and quality of new bone formation. In particular, Koh et al. demonstrated that 
using a rapamycin-inducible system to generate more sustained rhBMP-2 release from 
delivered fibroblasts results in better mineralization compared to uncontrolled 
constitutive expression of rhBMP-2 [218]. Furthermore, histological characterization in 
our study revealed that the new bone formed in the Col+rhBMP-2 group had a lamellar-
like structure, indicative of mature bone. This may suggest that the bone observed in the 
histological sections from the other two rhBMP-2 groups (GAG+BMP-2 MSC and 
GAG+rhBMP-2) had been deposited more recently and was possibly still actively 
(re)modeling at the 12-week time point. Interestingly, these observed differences in bone 
maturity and spatial distribution did not translate into functional differences between the 
three groups, in terms of the mechanical strength and stiffness of the regenerated femurs. 
A longer-term study may enable newly formed bone in all groups to progress to a similar 
stage of maturation and consequently result in quantifiable mechanical differences. 
Overall, these results suggest that GAG+BMP-2 MSC delivery remains a viable 
treatment strategy which is comparable to delivery of rhBMP-2 in collagen sponge in this 
pre-clinical model. 
Although GAG+BMP-2 MSC did not perform significantly better than 
Col+rhBMP-2 in this study, it is still remarkable that sufficient rhBMP-2 was released to 
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induce healing that was comparable to the 5 μg rhBMP-2 delivered on collagen sponge. 
The 5 μg dose was chosen because previous work from our group has demonstrated this 
to be the optimal healing dose in this rat segmental defect model [219]. However, we 
should acknowledge that this level of dosing is not reflective of clinical doses, which is 
often orders of magnitude higher (even after accounting for dose per weight) [220]. 
Recent work has shown that using higher doses of rhBMP-2 on collagen sponge in this 
model results in substantial ectopic bone formation [88], recapitulating one of the main 
adverse events associated with high dose rhBMP-2 use clinically. It remains to be seen 
whether this GAG gel system, which we demonstrated here to exhibit more sustained 
release compared to collagen sponge, would perform better at higher, more clinically-
relevant doses of rhBMP-2.  
These results add to a growing body of evidence concerning the importance of CS-
GAG to bone formation and BMP-2 signaling. While there has been some disagreement 
on the role of glycosaminoglycans in BMP-2 release, the sustained BMP-2 release profile 
from CS-GAG as compared to collagen may be explained by CS-GAG sulfation [221, 
222]. Wang et al. found that CS-modified collagen scaffolds were more hydrophilic and 
had greater surface energy than their unmodified counterparts, which they postulated 
contributed to higher initial release of rhBMP-2 in the first 8 hours [223]. This contrasts 
somewhat with the in vitro release we observed, but may indicate that sulfated GAGs 
play a role in rhBMP-2 stabilization. The importance of GAG sulfation is further 
reinforced by Hintze et al, who showed that CS with a higher degree of sulfation 
interacted with rhBMP-2 more strongly than their less sulfated counterparts for the same 
concentration [206], indicating that GAGs contributed to conformational and 
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thermodynamic stabilization of rhBMP-2 and as a result, enhanced rhBMP-2 signaling. 
This enhanced rhBMP-2 stabilization and signaling could help explain the presence of 
woven bone in defects treated with either CS-GAG group in our study. 
To our knowledge, this is the first study to investigate the suitability of CS-GAG 
hydrogels for rhBMP-2 delivery, and to mediate the regeneration of a critically-sized 
bone defect. Beyond the collagen scaffolds used clinically, there are a host of scaffold 
materials under development for BMP delivery [224]. Members of our group have 
previously demonstrated similar success in this same model with an alginate hydrogel  
[81]. In a study comparing rhBMP-2 delivery by chitosan and hyaluronic acid hydrogels, 
Luca et al showed greater bone formation by volume using hyaluronic acid, while the 
chitosan scaffold led to more mature bone [225]. While both materials are 
polysaccharides, chitosan is positively charged and hyaluronic acid is negatively charged 
– likely influencing their interactions with the positively charged rhBMP-2. Of these 
materials, hyaluronic acid is the most chemically similar to CS-GAG, with one of its key 
differences being a lack of sulfation. In a study examining rhBMP-2 release kinetics from 
hyaluronic acid, 100% of the protein was eluted within 1 week from a relatively slowly 
degrading gel [226], which reinforces CS-GAG’s advantages as scaffold for slow release 
of rhBMP-2. 
Our in vitro results demonstrated that the GAG+BMP-2 MSC system resulted in 
slower release compared to Col+rhBMP-2. Future studies could assess cumulative release 
at higher rhBMP-2 doses and more importantly, whether sustained release at higher doses 
is actually beneficial. In addition, one of the main concerns associated with rhBMP-2 use 
clinically is a heightened and uncontrolled inflammatory response [11, 90]. While this 
 119 
was not directly investigated in this study, MSC delivery may mitigate these risks, given 
MSCs have extensive immunomodulatory capabilities and can influence multiple 
immune cell types [227-230]. Future work exploring how MSC therapy may improve 
rhBMP-2-mediated bone healing by limiting adverse effects could be impactful for 
clinicians.  
Finally, this GAG+BMP-2 MSC system could potentially be enhanced further 
through incorporation of cell-adhesive ligands. In the context of bone repair, the 
fibronectin motif RGD [98] and the collagen-mimetic peptide GFOGER [231] have been 
shown to be effective in promoting new bone formation. These studies have 
demonstrated that including cell adhesion ligands in the biomaterial scaffold can improve 
healing for both rhBMP-2 delivery as well as cell delivery approaches. Shekaran et al. 
showed that GFOGER delivered with a low dose of rhBMP-2 actually increased 
recruitment of CD45-/CD90+ osteoprogenitor cells to a radial defect compared to 
collagen sponge with rhBMP-2 [232]. In addition, Moshaverinia et al. demonstrated that 
osteogenic differentiation of multiple types of MSCs was enhanced when the cells were 
encapsulated in RGD alginate microspheres compared to non-functionalized alginate 
[233]. For our study, we tested both rhBMP-2 and MSC delivery approaches with a non-
functionalized GAG gel and observed comparable healing to collagen sponge with 
rhBMP-2. Based on these findings from other labs, it seems plausible that functionalizing 
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Abstract 
This article examines publication trends in four states – California, Connecticut, 
Maryland and New York – with state stem cell funding programs and finds that both 
California and Connecticut account for a greater share of pluripotent stem cell related 
publications than they do in comparison fields not targeted by specific state policies. 
Introduction 
The isolation of human embryonic stem cells (hESCs) in 1998 intensified 
discussions about ethical issues associated with stem cell research and inspired a still-
ongoing global policy debate over the acceptability of and funding for various types of 
stem cell research [234]. In the U.S., three distinct federal funding policies – 
corresponding to the Clinton, Bush and Obama Administrations – have been adopted 
[234] and the policy environment has been further complicated by uncertainty associated 
with congressional action and litigation [235]. 
 Extensive policy action has also occurred at the state level in the U.S., with states 
both supporting and restricting stem cell research and related areas of scientific inquiry 
[236]. Six states—California, Connecticut, Illinois, Maryland, New Jersey, and New 
York—took the unusual step of dedicating state funding to support basic and translational 
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stem cell research (including research using hESCs) [237]. These state policies had 
several goals encompassing the advancement of science (including hESC research that 
could not be conducted with federal funding during the Bush Administration) and 
economic development priorities. Although stem cell funding programs in Illinois and 
New Jersey have ceased operations, funding programs of various sizes – ranging up to 
California’s $3 billion program – continue in the other four states (see Table 3 for details 
on these programs and data on their size relative to NIH funding in each state).  
Table 3 - Overview of four major state stem cell research funding programs. 
 California Connecticut Maryland New York 
First grants 
awarded 
2006 2006 2007 2008 
Initial funding / 
Time period 
$3B / 10 years $100M / 10 years N/A 








hESC $36M (28.8%) $4.4M (3.5%) $2.4M (2.0%) $7.9M (6.4%) 
SC $222M (20.3%) $21M (1.9%) $41M (3.8%) $108M (9.8%) 
All $3.3B (14.8%) $445M (2.0%) $1.6B (7.1%) $1.9B (8.6%) 
Notes: Approximate annual funding was calculated by dividing total commitment by time 
period of commitment for CA, CT and NY. Maryland’s approximate annual funding was 
calculated by dividing its total funding through July 2014 by its years of operation. For 
comparison, NIH funding received by each state for hESC, all stem cell (SC) and all 
extramural research is shown. The total dollar value of NIH funding was extracted from 
the NIH RePORT system (http://report.nih.gov/) and the share of all NIH extramural 
funding in that category was calculated from these data. 
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 Despite the scale of these programs, relatively little is known about their impact 
on the field. One exception is a 2010 assessment that found that between December 2005 
and the end of 2009, the programs collectively awarded approximately 750 grants 
totaling US$1.25 billion in state funding [237]. This assessment found wide variation 
(ranging from 21% in New York and New Jersey to 97% in Connecticut) among the 
states in the extent to which their grants focused on hESC research and suggested that 
one key success of the programs had been drawing new scientists into the field of stem 
cell research [237].  
   As some of these state programs are nearing the final years of their initial funding 
commitments, understanding their effects on the scientific enterprise is an increasingly 
important policy question. In this paper, we contribute to this effort by examining 
publications in stem cell related fields in the four states with sustained stem cell funding 
programs and comparing the share of hESC- and induced pluripotent stem cell (iPSC)-
related publications with the share of publications in other areas of biomedical research 
(RNAi- and cancer-related research) presumed to be less affected by state policies. In 
addition, we examine the funding sources acknowledged in both hESC- and RNAi-
related publications to assess how state funding contributed to the differences we 
observe. This analysis builds on a series of studies looking at the international 
distribution of stem cell publications generally [238-240] and the publication 
performance of the United States following the adoption of the restrictive funding policy 
in the Bush Administration more specifically [241, 242]. (See Supplemental 
Experimental Procedures for more information about our data collection and analysis 
strategies.) 
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Publications Trends Vary by State 
Figure 30 shows the share of U.S. hESC-, iPSC-, RNAi- and cancer-related 
publications with at least one author from California, Connecticut, Maryland or New 
York as well as the share of hESC-related publications acknowledging funding from each 
state. Table S1 shows the difference between each state’s share of hESC- and iPSC- 
related publications and its share of cancer-related publications broken into three 
timeframes. These timeframes were selected to represent the period when hESCs were 
under investigation but state policies had not yet been adopted (early hESC: 1998-2004), 
the period during which most state stem cell funding policies were adopted and awarded 
their initial grants (adoption: 2005-2008), and the period when these programs were up 
and running and, given time lags between funding and publication, their effects could 
plausibly be seen in the publication record (implementation: 2009-2013). 
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Figure 30 - Trends in state publication percentages for hESC, iPSC, RNAi and 
cancer-related research. 
 California’s share of publications in the two comparison groups was quite 
consistent. Between 15% and 18% of U.S. cancer-related publications had at least one 
author from the state in each two-year period assessed between 1996 and 2013 and, 
following an initial period of growth, the state’s share of RNAi-related publications 
remained between 17% and 19% from 2002 through 2013. The state’s share of hESC- 
and iPSC-related research differed markedly from its share of these comparison groups. 
Its share of hESC-related research exceeded its share of the comparison groups as early 
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as 2000-2001 and this difference continued to grow in future years, reaching a high of 
45% in 2010-2011. California’s share of iPSC-related research has been high since 
shortly after the technology’s discovery, with the state accounting for 44% of U.S. 
publications in 2008-2009. These differences are statistically significant in both the 
adoption and implementation time periods for hESC-related research and during the 
implementation period for iPSC-related research (P<0.01 for each test, see Table S1). 
After the California Institute for Regenerative Medicine (CIRM) issued its first grants in 
April 2006, the share of articles acknowledging California funding increased rapidly from 
approximately 3% in 2006-07 to more than 20% in 2010-11 and 2012-13. Overall, 
California state funding was acknowledged in nearly 19% of  all hESC-related articles in 
our dataset published between 2006 and 2013, compared with 1.8% of articles in a 
comparable set of RNAi-related research (t-test, P<0.01). 45% of the hESC-related 
articles published between 2006 and 2013 in our dataset with at least one author from 
California acknowledged funding from the state. 
 Similar trends were seen in Connecticut. The state’s share of cancer-related 
publications was relatively consistent, ranging from 2% to 3% throughout the time period 
studied, while the state’s share of hESC-related research grew from 0% in 2002-2003 to 
6% in 2012-13. Similar to California, Connecticut’s share of iPSC-related research 
publications exceeded its share of cancer-related research as early as 2008-2009 and, in 
Connecticut’s case, this difference continued to grow through 2012-2013. Overall, 
Connecticut state funding was acknowledged in 2.4% of  all hESC-related articles 
published between 2006 and 2013 in our dataset, compared with 0.2% of articles in the 
comparable set of RNAi-related research (t-test, P<0.01). 67% of the hESC-related 
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articles published between 2006 and 2013 in our dataset with at least one author from 
Connecticut acknowledged funding from the state. 
For Maryland and New York, in contrast, the share of hESC- and iPSC- related 
research in recent years was similar to the share of the two comparison groups. 
Maryland’s share of hESC-related research declined from a high of 22% in 2004-2005 to 
10% in 2008-2009 before leveling off. State funding from Maryland was acknowledged 
in 2.2% of the hESC-related articles published between 2006 and 2013 in our dataset, 
with most of these state-supported articles published between 2010 and 2013. In New 
York, the share of hESC-related research publications grew from a low of 8% in 2008-
2009 to 13% in 2012-2013 but, even following this growth, remained similar to the 
state’s share of publications in the two comparison groups. Funding from New York was 
also acknowledged in 2.2% of the hESC-related articles published between 2006 and 
2013 in our dataset and most of these articles were published between 2010 and 2013. 
Policy Considerations 
Our comparative analysis provides some of the first evidence that the distribution 
of stem cell related publications in the United States differs from the distribution of 
publications in fields not targeted by specific state funding policies, and our analysis of 
the funding sources acknowledged in many of these articles strongly suggests that state 
funding is responsible, in part, for these differences. The share of hESC- and iPSC-
related publications produced in each of the four states examined depends on a variety of 
considerations including the size, strengths, and interests of the scientific community and 
the specifics of the policy itself (i.e. its timing, its size, and its focus). In addition, it 
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depends on the competitive environment within the United States, as over-performance in 
one state must be balanced by under-performance in others. 
In both California and Connecticut, state funding programs appear to have 
contributed to over-performance in the field. In California’s case, the state was already a 
strong performer in hESC-related research before its state funding policy was adopted in 
2004 and funding began flowing in 2006. This may reflect a generally supportive state 
environment or a first-mover advantage, as Geron Corporation, a key funder of early 
hESC research, is based in the state. Following passage of Proposition 71 in November 
2004 and the creation of CIRM in the ensuing years, the state’s share of hESC-related 
research grew from approximately 25% in 2002-2003 to more than 40% and the state 
maintained this position of strength in both hESC- and iPSC-related research from 2008 
through the end of our data in 2013. Between 2010 and 2013, approximately 55% of 
hESC-related articles published with at least one California author acknowledged state 
funding, suggesting that this funding program played an important role as California 
maintained and built upon its early leadership in the field. The Connecticut case is even 
more suggestive of a policy impact, as the state showed very little hESC-related research 
activity through 2004-2005, and then showed steady growth in publication share 
following adoption of its funding policy in 2005, with approximately 67% of these 
articles acknowledging state funding. These findings align well with previous work [237] 
indicating that California and Connecticut, at least in the early years of their funding 
programs, focused more of their grants on hESC research than did other states. Given the 
close relationship between hESC and iPSC research [243], it is not surprising that, 
although iPSC cells were not explicitly prioritized by these state programs, these states 
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also produced a higher share of iPSC-related research than they did in the comparison 
fields.  
In contrast to California and Connecticut, over-performance in pluripotent stem cell 
research was not seen in Maryland and New York. Our analysis shows, however, that 
state funding from each of these states contributed to approximately 3% of the hESC-
related publications in our dataset between 2010 and 2013. This funding appears to have 
helped these states maintain a share of hESC-related research similar to their share in the 
comparison fields and, given the competitive environment with other states investing 
heavily in stem cell research, this may well be a successful policy outcome. 
 This analysis illustrating the relative performance of states in the production of 
stem cell related research publications provides a useful starting point for policymakers 
and, potentially, voters considering the future of state stem cell funding efforts as well as 
others interested in state science and technology policy more generally. We focused our 
analysis on hESC-related research as this field was a key motivation for some state stem 
cell funding programs [237], but future work could examine the effects of state stem cell 
programs on the broader fields of stem cell research and regenerative medicine. In 
addition, while we analyzed hESC-and iPSC-related research separately, these fields are 
closely intertwined [243] (see Supplemental Experimental Procedures for discussion) and 
future work could examine how state programs reacted to the development of iPSCs and 
prioritized their funding among these two related but distinct forms of pluripotent stem 
cell research. In addition, publications are only one measure of the impact of state science 
funding programs and examining other outcomes (e.g. patents awarded, clinical trials 
initiated, etc.) is an important topic for future research. Indeed more thorough efforts to 
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evaluate these state stem cell programs, ideally drawing on the initial goals of the 
programs and a wide range of relevant outcomes, would be an important step to help 
assess their impact on the field and the value of field-specific state science funding 
programs more generally. 
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